Specialists audit about 9A0-327 exam questions | braindumps | ROMULUS

Go through Pass4sure 9A0-327 Q&A and prepare all the practice questions - examcollection - and braindumps provided at website and forget failing the exam - braindumps - ROMULUS

Pass4sure 9A0-327 dumps | Killexams.com 9A0-327 existent questions | http://tractaricurteadearges.ro/

9A0-327 Adobe CQ 5.5 Component Developer ACE

Study steer Prepared by Killexams.com ADOBE Dumps Experts


Killexams.com 9A0-327 Dumps and existent Questions

100% existent Questions - Exam Pass Guarantee with high Marks - Just Memorize the Answers



9A0-327 exam Dumps Source : Adobe CQ 5.5 Component Developer ACE

Test Code : 9A0-327
Test cognomen : Adobe CQ 5.5 Component Developer ACE
Vendor cognomen : ADOBE
: 92 existent Questions

Save your time and money, read these 9A0-327 and engage the exam.
killexams.com tackled sum my problems. considering long questions and answers was a test. anyhow with concise, my making plans for 9A0-327 exam was virtually an agreeable enjoy. I efficiently passed this exam with 79% score. It helped me recall without lifting a finger and solace. The Questions & answers in killexams.com are fitting for bag prepared for this exam. a all lot obliged killexams.com in your backing. I could reflect onconsideration on for lengthy simply even as I used killexams. Motivation and high-quality Reinforcement of newcomers is one theme matter which i create tough buttheir abet compose it so smooth.


I exigency present day dumps modern-day 9A0-327 examination.
i am very elated with this package deal as I were given over 96% on this 9A0-327 exam. I read the official 9A0-327 manual a little, but I guess killexams.com was my foremost training resource. I memorized maximum of the questions and answers, and furthermore invested the time to certainly comprehend the scenarios and tech/practice targeted parts of the exam. I assume that by means of itself purchasing the killexams.com bundle does now not guarantee that youll pass your exam - and a few tests are sincerely tough. yet, in case you study their materials tough and surely placed your brain and your heart into your exam instruction, then killexams.com definitely beats any other exam prep options available out there.


Use genuine 9A0-327 dumps. mind dump and popularity does conclude not forget.
i am satisfied to bid that i maintain effectively passed the 9A0-327 exam. on this context I must admit that your questions and answers did assist (if now not completely) to tied over the exam because the questions asked within the exam maintain been not completely blanketed with the aid of your questions bank. however I should congratulate your pains to compose us technically sound together with your s. route to killexams.com for clearing my 9A0-327 exam in first class.


Use authentic 9A0-327 dumps with estimable character and reputation.
preparing for 9A0-327 books may exist a difficult process and 9 out of ten probabilities are that youll fail in case you conclude it with not anyone commandeer guidance. Thats where character 9A0-327 e bespeak comes in! It affords you with green and groovy data that no longer only complements your guidance however additionally offers you a antiseptic cleave hazard of passing your 9A0-327 download and stepping into any university with not anyone melancholy. I organized through this brilliant software and that iscored 42 marks out of 50. i will assure you that its going to by no means assist you to down!


simply those 9A0-327 ultra-modern dumps and engage a peer at manual is needed to pass the engage a peer at.
First of sum I want to yelp Thanks to you people. I maintain cleared 9A0-327 Exam by subscribing to your study materials. So I wanted to share my success on your website. Thank you once again. Thank you very much for your powerful support. I maintain cleared my 9A0-327 with 90%.


these 9A0-327 questions and answers provide proper expertise of subjects.
I maintain become a 9A0-327 certified closing week. This profession path is very exciting, so if you are nevertheless considering it, compose inevitable you bag questions answers to prepare the 9A0-327 exam. This is a massive time saver as you bag precisely what you exigency to recognize for the 9A0-327 exam. This is why I selected it, and I by no means seemed again.


I got Awesome Questions bank for my 9A0-327 exam.
Felt very arrogant to complete answering sum questions during my 9A0-327 exam. Frankly talking, I owe this achievement to the questions & answers by killexams.com The material blanketed sum the related questions to eachsubject bethink and provided the solutions in quick and unique manner. information the contents maintain arrive to exist antiseptic and memorizing became no wretchedness the least bit. I used to exist furthermore lucky enough to bag most of the questions from the guide. elated to pass satisfactorily. Wonderful killexams


Get those 9A0-327 existent exam questions and solutions! conclude now not bag rippoff
It ended up being a frail department of know-how to plot. I required a bespeak that may kingdom question and solution and that i absolutely allude it. killexams.com Questions & answers are singularly in freight of each ultimate one in sum credit. much obliged killexams.com for giving high character conclusion. I had endeavored the exam 9A0-327 exam for 3years constantly however couldnt compose it to passing marks. I understood my hollow in information the difficulty of makinga consultation room.


I feel very confident by preparing 9A0-327 actual test questions.
i maintain handed the 9A0-327 exam with this! this is the primary time I used killexams.com, however now I recognise its not gonna exist the closing one! With the exercise exams and actual questions, taking this exam turned into extraordinarily easy. that is a extremely estimable manner to bag certified - which might exist not anything dote whatever else. If youve been through any in their checks, youll understand what I imply. 9A0-327 is hard, but killexams.com is a blessing!


I feel very confident with 9A0-327 question bank.
while my 9A0-327 exam became prerogative beforehand of me, I had no time left and i used to exist freaking out. i was cursing myself for losing so much time earlier on vain dump however I had to conclude something and therefore I could only considerone element that might store me. Google informed that, the aspect turned into killexams.com. I knew that it had the all lot that a candidate could require for 9A0-327 exam of ADOBE and that helped me in accomplishing precise markssinside the 9A0-327 exam.


ADOBE Adobe CQ 5.5 Component

Adobe Drives personalized net, cell and convivial engagement with net event administration solution | killexams.com existent Questions and Pass4sure dumps

SALT LAKE city--(business WIRE)--Adobe systems integrated (NASDAQ:ADBE) today announced the supply of an stupendous update to its web journey management (WEM) answer, a Part of the Adobe® Digital advertising Suite. At a time when marketing budgets are below strict scrutiny and a one-size-matches-all strategy to achieving purchasers is not any longer acceptable, the WEM solution helps businesses pressure engagement via supplying extra consistent, contextually principal experiences on the web, cellular devices and convivial media.

via a unique aggregate of the latest Adobe Digital marketing Suite items and capabilities, Adobe WEM empowers marketers, in partnership with IT, to rapidly customize manufacturer and e-commerce experiences, optimize landing pages and micro sites, and maintain interaction in convivial communities and conversations. The newest concede carries:

  • easy-to-use, unified web content material administration (WCM) that helps entrepreneurs leverage consumer context to personalize online experiences and more advantageous gain digitally immersed purchasers
  • creative HTML5 cellular utility publishing assist for the rapid, simultaneous launch of content across websites, cellular websites and smartphone and pill apps
  • enterprise-class Digital Asset administration (DAM) intuitively integrated with Adobe artistic tools and the drawing close Adobe inventive Cloud™ to streamline introduction and re-use of prosperous media
  • at the heart of the WEM solution is Adobe CQ, a identified industry chief in WCM software built on open specifications. the brand novel Adobe CQ 5.5, available these days, significantly builds on this management dwelling through several improvements, as well as integration with different products within the Digital marketing Suite, together with perception for inspecting large volumes of information in actual-time; Scene7® for converting wealthy media to dynamic content material optimized throughout channels; Search&Promote for centered site search and surfacing principal product and content material fits; SiteCatalyst® for actionable online analytics; and peer at various&target™ for web page optimization and personalization. moreover novel e-commerce capabilities delivered by means of an open framework and partnership with market-chief, hybris (see part unencumber), Adobe CQ 5.5 advances include:

  • customer Context—deliver contextualized content material and consistent company experiences as clients flux from channel-to-channel and machine-to-gadget. Harnessing wealthy profile, segmentation and analytics records from the Adobe Digital advertising Suite, client Context empowers digital entrepreneurs to create, preview and optimize the personalized adventure of target consumer audiences.
  • cell App development—Empower advertising and marketing to rapidly create HTML5-primarily based cellular apps through novel integration with PhoneGap, Adobe’s requirements-based framework for structure cross-platform apps. Intuitive, drag-and-drop performance takes complete information of device elements, such because the accelerometer, camera and GPS.
  • DAM—allow collaboration on wealthy media belongings, including video, past the borders of the corporation. entrepreneurs can readily find, share, add feedback to, and revise and do up belongings in spite of layout, rushing time to market on digital campaigns. Now comprises integration with Adobe creative Suite® tools, in addition to Adobe artistic Cloud, which is anticipated in the first half of 2012.
  • Cloud manager (beta)—make positive optimal efficiency sum over peak customer claim by means of getting rid of bottlenecks and accelerating time-to-market on novel campaigns. novel cloud provider enables marketers to engage control of fluctuating top client site visitors whereas minimizing turnaround time of key on-line initiatives.
  • prices

    Kevin Cochrane, vp of Product strategy and solution advertising and marketing, Adobe

  • “internet content administration as we’ve universal it just doesn’t reduce it any more. not for CMOs tasked with improving corporate photo and contributing to the basis line in an age when the expectations of the CEO and consumer maintain under no circumstances been superior. and positively no longer for patrons who forecast tremendously pertinent assistance at the correct time, even if on a desktop, pill, or smartphone. Their internet journey management concede and Adobe CQ 5.5 were built with this in mind, and supply nowadays’s digital marketer the power to customize each and every event, across channels, to construct brand, power demand, and attain novel audiences.”
  • Dan investigate, director of expertise, Slate

  • “On any given day, Slate.com can exist required to serve over 1,000,000 page views per hour. readily put, they exigency to believe that their web content material management gadget is rock solid, and Adobe CQ has been simply that. Advances within the newest edition and the WEM concede will aid corporations such as ours ebb even extra in terms of inspecting and optimizing content material for readers. And with mobile birth a must-have, the capacity to directly submit HTML5 apps to sum systems will exist big.”
  • Matt Leopold, director of consumer adventure, TE Connectivity

  • “As a multi-billion dollar business with many audiences and hundreds of websites worldwide, it’s significantly essential for us to bring a unified event to their purchasers, despite the dwelling and the route they engage. They additionally exigency to exist positive the content they deliver is vital to who they're and what they should accomplish with us. It’s no minute feat, but it’s additionally a requirement. Adobe WEM and CQ 5.5 are in reality business class and upward thrust to this challenge.”
  • Andy Jacobs, government vice president and chief technology officer, MRM

  • “MRM’s stalwart perception is that the day a site launches is ‘Day 1.’ The actual merits of an business content material administration paraphernalia deployment are realized after the launch via an clever figuring out of the guests’ site behaviors and the confirmed optimization of the web page’s content material and consumer journey. The WEM concede and integrations with other Adobe applied sciences supply us and their consumers the vigor to focus their marketing optimization efforts basically on the client, continuously delivering the absolute best customer journey within the most aggressive timelines and charge range.”
  • Piyush Patel, director of technology, SapientNitro

  • “With the release of CQ 5.5 and the latest WEM solution, Adobe has created a more built-in digital advertising providing, enabling their theory Engineers to design, create, deliver, and measure these experiences in precise-time, and giving their shoppers the aggressive edge necessary in a swiftly altering economic climate. We’re overjoyed to exist partnering with Adobe on this video game-changing advancement and looking ahead to working collectively to deliver imaginative and measurable results for their joint purchasers.”
  • advantageous hyperlinks

    Availability

    Adobe WEM and Adobe CQ 5.5 are automatically obtainable on a global basis.

    in regards to the Adobe Digital advertising Suite

    The Adobe® Digital advertising Suite offers an built-in and open platform for on-line enterprise optimization, a technique for the usage of consumer insight to pressure innovation during the business and enhance advertising effectivity. The Suite incorporates built-in functions to bring together and unleash the energy of consumer perception to optimize customer acquisition, conversion and retention efforts as smartly because the creation and distribution of content. as an instance, the expend of the Suite, entrepreneurs can determine probably the most useful marketing options and advert placements as well as create primary, personalised and constant client experiences throughout digital advertising channels, such as onsite, reveal, electronic mail, social, video and cell. The Suite permits entrepreneurs to compose short alterations, automate inevitable client interactions and more desirable maximize advertising and marketing ROI, which, sooner or later, can positively maintain an result on the final analysis.

    About Adobe techniques included

    Adobe is altering the region through digital experiences. For greater tips, consult with www.adobe.com.

    © 2012 Adobe systems included. sum rights reserved. Adobe, the Adobe emblem, creative Cloud, Scene7, SiteCatalyst, verify&goal and artistic Suite are either registered emblems or logos of Adobe methods integrated in the u.s. and/or different international locations. sum other logos are the property of their respective house owners.

    pictures/Multimedia Gallery available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50211180&lang=en


    A glimpse of Adobe event supervisor | killexams.com existent Questions and Pass4sure dumps

    what's AEM?

    Adobe adventure manager (AEM) is a Java-based mostly content management platform technology which is a component of Adobe’s Digital advertising Cloud provider. It enables the person to create its own web site and the entire related purposes on one platform equivalent to mobile apps, types, and on-line communities. Adobe relish manager target prerogative customer with commandeer probability at commandeer time via their personalized campaigns and aid to achieve the business target.

    heritage of AEM

    Adobe journey manager become formerly called CQ5(Day Communiqué). A Swiss enterprise Day application in early 2000 began the CQ5 with the identify “communique” generally comprehend as “CQ”.

    Adobe paraphernalia in 2010 received Day application company and named it AEM. AEM maintain numerous edition 5.4, 5.5, 5.6, 6.0, 6.1, 6.2, 6.3 and 6.four (In-development).

    Why expend AEM?

    AEM is likely one of the fastest-starting to exist web platforms today and is used majorly by route of many companies. It offers the person with lots of primary add-ons to create a site with every other exciting facets dote storing the content facts from convivial media sites such as Twitter or Instagram. the mixing of Livefyre with AEM offers you a further advantage as you bag a lot of further add-ons which compose your web page tremendous fascinating in your shoppers. It contains component dote carousel, media-wall, mosaic, chat and lots greater. the combination of user Generated content material(UGC) with AEM allows for you to search for the convivial media content material and it can furthermore add it to your website with out making you leave your platform. AEM furthermore maintain some wintry aspects comparable to wise tagging for the asset, content fragment images along with the jpeg picture (for more info maintain a peer at this spectacular video: https://video.television.adobe.com/v/18280/).

    how it works?

    AEM is actually a cloud based client-server system for structure business grade web sites and functions. The working AEM server is continually talked about for example. There are really two cases of the AEM server viz. author and submit example. essentially sum the web site administration drudgery is executed on the writer instance. And for the conclusion-user to behold your content material you should do up the web page, which is referred as do up illustration.

    The system contains an integrated internet-based mostly construction environment dote CRXDE Lite (this has its own UI, the performance of which is akin to the basic UI used for authoring and administering).

    What’s the final analysis?

    AEM is among the most useful paraphernalia to build a constant product with the dynamically altering market which furthermore helps you create your own very own web page to fill your consumer requirement. it is a complete out-of-the-box solution which offers you the flexibleness to trade your lessons prerogative now and might engage your advertising and marketing strategy implementation time prerogative down to mere few hours from weeks and months.


    The Adobe artistic Cloud FAQ | killexams.com existent Questions and Pass4sure dumps

    The subsequent technology of Adobe’s inventive Suite purposes — together with highest character pro , Photoshop, and After consequences — is going to exist radically diverse that what you’re used to. That’s since the subsequent era of artistic Suite is called inventive Cloud, and furthermore you’ll now not purchase your apps, however subscribe to them.

    confused? itsy-bitsy doubt. That’s why we’ve created this constructive FAQs article.

    what is inventive Cloud and the route will it work?

    AdobeCreativeCloudAdobe is making sum updated artistic Suite items purchasable fully by route of the creative Cloud, an internet subscription model that requires a month-to-month license payment. To steer transparent of alienating users, dote Apple did with remaining reduce professional X, Adobe will accurately proceed to promote CS6-degree items and suites. those could exist completely supported, however no longer up-to-date.

    items received by route of the inventive Cloud are downloaded and do in on your laptop, identical to existing purposes. which you can deploy working types of subscribed apps on two computers at a time, whether or not they’re Macs, windows, or both. if you try to installation any CC utility on a third computing device, you’ll ought to signal out from one among your other two licensed computers.

    How conclude I subscribe?

    which you could exist Part of the creative Cloud on a yearly or monthly groundwork. in case you exist a Part of each year, your computer has to contact Adobe each ninety nine days to assess the license. if you are going to buy month-to-month, your computer has to symptom in every 30 days. sum you exigency is a web connection and it should engage dwelling instantly. no doubt there could exist diverse, tremendously publicized “my software quit working on the worst feasible time although i was utterly licensed” stories, however Adobe has luminous folks and they’ll drudgery difficult to lower these occurrences.

    when you depart the creative Cloud, your purposes discontinue working, but any endemic or cloud-based info you labored on are yours to retain.

    which you can lease any solitary application or the all creative Cloud, however there are not any sub-suites as there were before. It’s either one product or the all enchilada. as soon as a member, you’re free to down load and installation any utility at any time. Adobe will archive older versions of the utility on the creative Cloud, so you gained’t exist compelled to upgrade to more recent versions earlier than you’re in a position.

    What purposes are in Adobe inventive Cloud?

    during the past, you might buy individual artistic Suite applications or bundled collections. The simplest two that contained video editor optimum professional were production top class and master assortment. As you could behold in table 1, production premium become sum about production-category applications, where the master assortment included apps that enabled the rise experience, plus Fireworks, one other picture editor.

    artistic Cloud contains sum tools within the grasp collection, plus Muse, a novel internet design tool, and two a yoke others. You’ll furthermore bag many different paraphernalia and capabilities, together with 20GB of cloud storage. With artistic Cloud, you both license a solitary utility or the equal of the master collection; there’s no in between.

    Suite and Creative Cloud components

    Suite and inventive Cloud accessories

    What does Adobe artistic Cloud cost?

    As proven below, pricing depends on no matter if or not you’re upgrading, and even if you’re purchasing month-to-month or making a yearly commitment. exist alert that in case you compose an annual dedication and later cancel, you’ll exist charged 50 p.c of the ultimate quantity left for your contract.

    Creative Cloud pricing

    inventive Cloud pricing

    if you’re a novel purchaser making an annual commitment, the basis rate for the total artistic Cloud is $forty nine.ninety nine per 30 days. if you’re upgrading from CS6, the primary yr is $19.ninety nine per month, and if you’re upgrading from CS3-CS5.5, the primary 12 months is $29.ninety nine monthly. In each cases, after the primary year, the charge adjusts to $forty nine.99 monthly.

    in case you buy the inventive Cloud on a month-to-month foundation, the expense is $seventy four.99 per month. if you purchase a solitary utility on an annual contract, the month-to-month expense is $19.99 per thirty days, notwithstanding you could qualify for $9.ninety nine monthly pricing for the first 12 months in case you’re upgrading from any CS3 or newer product and making a complete year dedication. Month-to-month pricing on a solitary utility is $29.ninety nine per month.

    notice that the $19.ninety nine monthly first yr educational pricing expires on June 25; if you wait until the autumn quarter to exist Part of the creative Cloud, your pricing may exist $29.ninety nine per month. if you conclude symptom in for the special, your cost will alter to the $29.ninety nine per thirty days perpetual pricing after one year. sum other better presents expire on July 31, 2013.

    How does artistic Cloud subscription pricing compare to perpetual licensing?

    The reply depends on which product you’re upgrading from (if any) and the classification of buy that you’re making. Any evaluation furthermore depends upon how lengthy you are expecting to expend the bought product, as well because the charge that you apportion to the add-ons of the inventive Cloud that you just bag as a Part of membership. Any rate comparison ignores the fact that if you buy, you’re buying CS6, which is ready two years ancient, while in case you exist Part of the inventive Cloud, you’re leasing (in essence) CS7.

    listed here are some ordinary situations with 12-, 24-, and 36-month cost comparisons. sustain in mind that once buying, you exigency to lay the cash out now, whereas the hire selection spreads funds out.

    New buyer

    if you’re a very novel buyer, that you may either purchase a solitary CS6 product or suite or unite the creative Cloud and bag probably the most concurrent version of the product or products that you simply’re buying. here’s what the numbers loom to be.

    New editors, buy vs. lease

    New editors, buy vs. lease

    if you’re buying most advantageous seasoned only, the breakeven point occurs after the three year point. if you purchase production top class, the breakeven aspect furthermore occurs after three years, but if you opt for the inventive Cloud membership you bag entry to many extra products. if you exigency the entire apps within the master assortment, the artistic Cloud with an annual commitment is certainly the top-rated alternative.

    in case you intend to maintain the purposes for the complete three years, making the annual dedication is the route to go.

    improve From CS5 or CS5.5

    in case you own CS5 or CS5.5 versions of most commandeer or any suite, that you may better to CS6 with very favorable pricing. For models just before that, there is no better pricing for procuring CS6 items or suites. prerogative here’s how the numbers compare for CS5 or CS5.5 house owners selecting between buying CS6 or becoming a member of the artistic Cloud.

    Upgraders from versions 5 and 5.5, buy vs. lease

    Upgraders from models 5 and 5.5, purchase vs. lease

    The notably favorable better pricing that Adobe offers makes the artistic Cloud membership appears usurious by evaluation, peculiarly for those purchasing on a month-to-month basis. version 5.0 and especially 5.5 house owners will maintain to engage a tough look to exist at the novel features in the inventive Cloud types of key applications to peer if they justify going the inventive Cloud route.

    upgrade from CS3 or CS4

    in this class, it’s the inventive Cloud better coverage that appears dote manna from heaven: You bag the total 12 month pricing smash for any solitary or suite product from CS3 ahead. As mentioned, CS6 upgrade pricing most efficient applies to CS5 and CS 5.5, which skill you’re paying complete expense for the bought utility. prerogative here’s what the numbers loom to be.

    Upgraders from CS3 or CS4, buy vs. lease

    Upgraders from CS3 or CS4, purchase vs. hire

    clearly, until you reckon you’ll exist using the application for longer than 3 years (making it 5 years ragged on the time), the inventive Cloud selection is more favorable.


    Whilst it is very arduous assignment to elect dependable exam questions / answers resources regarding review, reputation and validity because people bag ripoff due to choosing incorrect service. Killexams. com compose it inevitable to provide its clients far better to their resources with respect to exam dumps update and validity. Most of other peoples ripoff report complaint clients arrive to us for the brain dumps and pass their exams enjoyably and easily. They never compromise on their review, reputation and character because killexams review, killexams reputation and killexams client self confidence is Important to sum of us. Specially they manage killexams.com review, killexams.com reputation, killexams.com ripoff report complaint, killexams.com trust, killexams.com validity, killexams.com report and killexams.com scam. If perhaps you behold any bogus report posted by their competitor with the cognomen killexams ripoff report complaint internet, killexams.com ripoff report, killexams.com scam, killexams.com complaint or something dote this, just sustain in mind that there are always atrocious people damaging reputation of estimable services due to their benefits. There are a large number of satisfied customers that pass their exams using killexams.com brain dumps, killexams PDF questions, killexams exercise questions, killexams exam simulator. Visit Killexams.com, their test questions and sample brain dumps, their exam simulator and you will definitely know that killexams.com is the best brain dumps site.

    Back to Braindumps Menu


    000-669 test prep | NNAAP-NA free pdf download | 1T6-323 sample test | HP3-C40 exercise test | ACNP study guide | JN0-314 dump | 000-545 mock exam | 000-011 existent questions | MB4-212 exercise test | 1Z0-868 test prep | 000-754 questions and answers | HP0-A03 free pdf | C2140-646 exercise questions | 6101-1 brain dumps | NCLEX questions answers | CCA-505 existent questions | 1V0-605 braindumps | 1Z0-048 pdf download | 000-294 cram | C9010-022 existent questions |


    Review 9A0-327 existent question and answers before you engage test
    We are an awesome arrangement cognizant that most wretchedness inside the IT business is that there is a nonattendance of modest and powerful investigation material. Their exam prep material gives sum of you that you should engage an accreditation exam. Their ADOBE 9A0-327 Exam will reason of exam questions with indicated arrangements that mirror the existent exam. high gauge and motivation for the 9A0-327 Exam. They at killexams.com are set out to allow you to pass your 9A0-327 exam.

    We maintain Tested and Approved 9A0-327 Exams. killexams.com provides the foremost actual and most up-to-date IT braindumps that much accommodate sum info focuses. With the steer of their 9A0-327 exam dumps, you conclude not exigency to squander your chance on spending time on reference books and easily maintain to exist compelled to disburse 10-20 hours to ace their 9A0-327 existent Questions and Answers. Whats more, they maintain an approach to outfit you with PDF Version and Exam Simulator Version test Questions and Answers. For Exam Simulator Version dumps, Its offered to resign the candidates mimic the ADOBE 9A0-327 exam in an exceedingly existent scenario. killexams.com Discount Coupons and Promo Codes are as under; WC2017 : 60% Discount Coupon for sum exams on website PROF17 : 10% Discount Coupon for Orders larger than $69 DEAL17 : 15% Discount Coupon for Orders larger than $99 SEPSPECIAL : 10% Special Discount Coupon for sum Orders Click http://killexams.com/pass4sure/exam-detail/9A0-327

    Astounding 9A0-327 items: they maintain their specialists Team to guarantee their ADOBE 9A0-327 exam questions are dependably the most recent. They are on the all exceptionally acquainted with the exams and testing focus.

    How they sustain ADOBE 9A0-327 exams updated?: they maintain their unique approaches to know the most recent exams data on ADOBE 9A0-327. Now and then they contact their accomplices extremely cozy with the testing focus or in some cases their clients will email us the latest criticism, or they got the most recent input from their dumps advertise. When they ascertain the ADOBE 9A0-327 exams changed then they update them ASAP.

    Unconditional promise?: if you truly arrive up short this 9A0-327 Adobe CQ 5.5 Component Developer ACE and don't exigency to sit taut for the update then they can give you complete refund. Yet, you ought to dispatch your score concede to us with the goal that they can maintain a check. They will give you complete refund promptly amid their working time after they bag the ADOBE 9A0-327 score report from you.

    ADOBE 9A0-327 Adobe CQ 5.5 Component Developer ACE Product Demo?: they maintain both PDF variant and Software adaptation. You can check their product page to perceive what it like.

    killexams.com Huge Discount Coupons and Promo Codes are as under;
    WC2017: 60% Discount Coupon for sum exams on website
    PROF17: 10% Discount Coupon for Orders greater than $69
    DEAL17: 15% Discount Coupon for Orders greater than $99
    DECSPECIAL: 10% Special Discount Coupon for sum Orders


    At the point when will I bag my 9A0-327 material after I pay?: Generally, After efficient installment your username/secret key are sent at your email address inside 5 min. In any case, if any deferral in bank side for installment approval, at that point it takes minimal longer.

    9A0-327 Practice Test | 9A0-327 examcollection | 9A0-327 VCE | 9A0-327 study guide | 9A0-327 practice exam | 9A0-327 cram


    Killexams 000-Z05 mock exam | Killexams ABEM-EMC existent questions | Killexams HP0-757 cram | Killexams 111-056 questions and answers | Killexams LOT-980 study guide | Killexams 156-706 braindumps | Killexams 3104 brain dumps | Killexams TMPTE exercise questions | Killexams 000-010 exercise Test | Killexams 1Y0-259 study guide | Killexams ST0-47W test prep | Killexams E20-020 dumps | Killexams VCP-410 free pdf | Killexams 70-342 braindumps | Killexams 3X0-203 exercise test | Killexams 000-735 free pdf | Killexams 1Z0-101 exam prep | Killexams A2090-610 examcollection | Killexams MB4-211 brain dumps | Killexams A2040-410 existent questions |


    killexams.com huge List of Exam Braindumps

    View Complete list of Killexams.com Brain dumps


    Killexams C2150-196 cram | Killexams NS0-511 bootcamp | Killexams CSQE free pdf | Killexams 000-723 test questions | Killexams 70-569-CSharp study guide | Killexams DANB cheat sheets | Killexams 200-550 brain dumps | Killexams 1Z0-547 free pdf download | Killexams SCNP-EN test prep | Killexams 920-452 sample test | Killexams LOT-412 exercise questions | Killexams DC0-260 exercise test | Killexams A2090-312 exam questions | Killexams E20-559 exercise exam | Killexams C9520-923 questions answers | Killexams 70-543-CSharp existent questions | Killexams ICTS exercise test | Killexams JK0-U31 brain dumps | Killexams EADA10 dump | Killexams C2040-407 free pdf |


    Adobe CQ 5.5 Component Developer ACE

    Pass 4 positive 9A0-327 dumps | Killexams.com 9A0-327 existent questions | http://tractaricurteadearges.ro/

    ASUS ZenBook Pro 15 UX580 Ditches The Touchpad For A 5.5-inch panoply | killexams.com existent questions and Pass4sure dumps

    ASUS' ZenBook Pro 15 UX580 laptop has debuted and it is packing what it calls the ScreenPad. This feature takes the spot that would normally exist reserved for a measure touchpad and turns it into a secondary screen that can panoply its own data. The ScreenPad is a 5.5-inch complete HD IPS panoply with custom controls for apps dote Office and YouTube.

    While it can act as a secondary screen for control of some programs, it still retains complete uphold for Microsoft Precision Touchpad and gestures supporting up to four fingers. A configurable toolbar at the top of the ScreenPad can exist dragged down to access the app launcher, which is configurable for any installed app. uphold for professional apps is integrated out of the box including Word, Excel, and PowerPoint along with a calendar app that syncs with a Windows calendar account. ASUS plans to launch a ScreenPad SDK by the discontinue of 2018 to animate developers to uphold the novel feature. ScreenPad furthermore supports the ASUS Pen.

    The notebook has up to an 8th generation Intel Core i9 processor, NVIDIA GeForce GTX 1050 Ti discrete graphics with 4GB of GDDR5 memory, PCIe-based storage, and DDR4-2400 RAM. Wireless networking is 802.11ac Wave 2 gigabit and the laptop has Thunderbolt 3 USB Type-C ports. Buyers can opt for up to a 4K panoply with 100% Adobe RGB color space coverage and 132% of sRGB. NanoEdge bezels on the screen give an 83% screen-to-body ratio. The audio system features Harmon Kardon-certified ASUS SonicMaster tech promising a frequency gain 1.4 times louder and 1.6 times wider than the previous generation ZenBook Pro. 

    ASUS plans to ship the ZenBook Pro 15 UX580 in mid-July at $2,299 via the ASUS store and other retailers.

    Via:  ASUS

    ').insertAfter(jQuery('#initdisqus')); } loadDisqus(jQuery('#initdisqus'), disqus_identifier, url); } else { setTimeout(function () { disqusDefer(); }, 50); } } disqusDefer(); role loadDisqus(source, identifier, url) { if (jQuery("#disqus_thread").length) { jQuery("#disqus_thread").remove(); } jQuery('').insertAfter(source); if (window.DISQUS) { DISQUS.reset({ reload: true, config: role () { this.page.identifier = identifier; this.page.url = url; } }); } else { //insert a wrapper in HTML after the relevant "show comments" link disqus_identifier = identifier; //set the identifier argument disqus_url = url; //set the permalink argument //append the Disqus embed script to HTML var dsq = document.createElement('script'); dsq.type = 'text/javascript'; dsq.async = true; dsq.src = 'https://' + disqus_shortname + '.disqus.com/embed.js'; jQuery('head').append(dsq); } jQuery('.show-disqus').show(); source.hide(); }; role disqusEvent() { idleTime = 0; } Please enable JavaScript to view the comments powered by Disqus. blog comments powered by

    Day Software Expands U.S. Operations and Moves Headquarters to Boston | killexams.com existent questions and Pass4sure dumps

    By business Wire

    Article Rating:

    December 1, 2009 09:40 AM EST

    Reads:

    1,437

    Day Software (SIX: DAYN, OTCQX: DYIHY), a leading provider of content management and content infrastructure software, today announced the relocation of its U.S. headquarters from Newport Beach, Calif. to Boston, Mass. Day’s novel Boston headquarters will serve as a hub for sales, marketing, and services to uphold Day’s growing business in the U.S. and exist the primary location for Day’s U.S.-based senior executive staff. Day is celebrating the novel location today with a august opening event hosted by Day’s executive team at 320 Congress Street in Boston's Seaport District, adjacent to Boston's Waterfront and pecuniary Districts. Day's Newport Beach operations continue as the company's regional office for the West Coast.

    Day has seen significant growth in the U.S. market in 2009. Following the release of its award-winning CQ5 platform, Day reported record customer adoption in H1 2009 and break-out license revenue growth of 70% percent in Q3 2009. Day’s growth in the U.S. market has been propelled by the addition of marquee customer accounts over the course of 2009, including Adobe, generic Motors (GM), Newsweek, U.S. Army, RosettaStone, Ingersoll-Rand, Arbella, Newedge Group, Nemours Foundation, National bucolic Utilities Cooperative, RAND Corporation, University of Cincinnati, University of Buffalo and Boston College. Day furthermore experienced significant growth as a result of expanded deployments within its installed based with major re-orders from such customers as City of Chicago, F5 Networks, Williams-Sonoma, and Intercontinental Hotel Group (IHG).

    “Fueled by their ongoing success in the U.S., relocating their expanded headquarters to Boston signals the next stage of their growth,” said Erik Hansen, CEO of Day Software. “Boston has a thriving technology ecosystem and is the exemplar dwelling for their U.S. operations. They are very much looking forward to joining and collaborating with the community of innovators in the area.”

    About Day

    Day Software is the ECM pioneer that leading global enterprises rely on for their Web 2.0 content application and content infrastructure needs. Day’s Content Repository Extreme (CRX) is the industry’s leading Java Content Repository (JCR) and provides unique virtualization services to consolidate legacy repositories and unique cloud computing services to lower IT operational costs. Day’s Communique CQ5 provides industry-leading Web Content Management, Digital Asset Management, and convivial Collaboration in a single, unified suite and won the 2009 InfoWorld Technology of the Year Award for “Best Web CMS”.

    Day is an international company with headquarters in Basel, Switzerland and Boston, Massachusetts, traded since April 2000 on the SIX Swiss Exchange, and “Over the Counter” (OTC) as American Depositary Receipts (OTCQX:DYIHY). Day’s customers are worldwide leading global enterprises, including: Volkswagen, Daimler, Nissan, Chanel, Allianz, Vodaphone, LaPoste, Time, Inc., University of Phoenix, and InterContinental Hotels. For more information, visit Day on the Web at www.day.com and result the company on Twitter @daysoftware.


    InPlay from Briefing.com | killexams.com existent questions and Pass4sure dumps

    9:54 am generic Motors drops -3.5% to challenge its 200-day/50-day moving impartial cluster around 34.75 region (GM) :  

    The major averages opened Tuesday's session in positive territory with the S&P 500 sporting a gain of 0.2%.

    Most sectors trade in the green this morning with energy (-0.1%), health freight (-0.1%), and materials (-0.1%) being the only laggards. The heavily-weighted pecuniary sector (+0.3%) is demonstrating relative energy for the second day in a row, extending its week-to-date gain to 1.0%. The existent estate space is the top performer, up 0.7%.

    U.S. Treasuries maintain ticked up recently in a curve-flattening trade. The 10-yr capitulate is unchanged at 2.30% while the 2-yr capitulate is lower by one basis point at 1.34%.

    9:36 am generic Motors reports July total sales of -15% YoY to 226107 units (GM) :

    9:30 am Qualys to acquire Nevis Networks (QLYS) : . This asset purchase is expected to provide significant domain expertise in passive scanning technologies and allow Qualys to accelerate its scurry into the adjacent market of mitigation and response at endpoints. Nevis has built a string of high performance security products that extend similar levels of protection create in the perimeter to sum users on enterprise LANs. Qualys expects the transaction to close during the third quarter of 2017.

    The invert stock split will become efficient at 5:00 p.m. EDT on August 1, 2017. theme to the satisfaction of customary closing conditions, the closing of the merger with Molecular Templates is expected to occur shortly following the effectiveness of the invert stock split.

    Highlights (U.S. Sales):

    9:17 am S&P futures vs honest value: +8.80. Nasdaq futures vs honest value: +25.60. (:WRAPX) :

    Buyers maintain the edge this morning following Monday's mixed finish and ahead of Apple's (AAPL 149.10, +0.37) latest earnings report, which will exist released following the closing bell. The S&P 500 futures currently trade nine points, or 0.4%, above honest value.

    U.S. Treasuries are trading lower after June personal income missed expectations (0.0% actual vs +0.3% Briefing.com consensus). However, June personal spending (+0.1%) and the June core PCE charge Index (+0.1%) both met expectations. The benchmark 10-yr capitulate is two basis points higher at 2.31%.

    Investors will receive two additional pieces of economic data today--June Construction Spending (Briefing.com consensus 0.5%) and the July ISM Index (Briefing.com consensus 56.2). Both reports will exist released at 10:00 ET. furthermore of note, July auto and truck sales will exist released throughout the day.

    In U.S. corporate news, Pfizer (PFE 33.10, -0.06) is down 0.2% in pre-market action after a mixed earnings report; the Dow component beat earnings estimates but fell short of revenue expectations. Meanwhile, Under Armour (UAA 19.03, -1.01) has dropped 5.0% after announcing a restructuring draw and lowering its guidance for the fiscal year.

    Elsewhere on the earnings front, Cummins (CMI 158.50, -9.47) has tumbled 5.6% this morning after missing earnings estimates, Simon Properties (SPG 162.05, +3.55) is up 2.2% after beating bottom-line estimates, and Sprint (S 8.34, +0.36) is up 4.1% after beating earnings expectations and raising its profit guidance.

    Crude oil's six-session winning vein is in danger as the commodity currently trades lower by 0.4% at a charge of $49.93/bbl. Meanwhile, the U.S. Dollar Index (92.83, +0.16) is higher by 0.2%.

    9:17 am Navient acquires Duncan Solutions, a transportation revenue management company serving municipalities and toll authorities w/ approx. $55 mln in annual revs, for approx. $80 mln (NAVI) :  

    9:14 am TEGNA beats by $0.02, reports revs in-line; sees Q3 revs declining in high-single to low-double digits (TGNA) :

    9:13 am Peapack-Gladstone pecuniary acquires Gladstone, NJ-based, Murphy Capital Management, a SEC Registered Investment Adviser, efficient August 1, 2017 (PGC) : With a combined market value of approximately $4.7 billion of client assets under management and administration, and offices in Bedminster, Gladstone, Morristown, Princeton and Teaneck, as well as a faith office in Greenville, Delaware, the private wealth management division of Peapack-Gladstone Bank is the largest novel Jersey-headquartered, bank-owned faith company in the state.

    9:09 am I.D. Systems acquires Keytroller, a manufacturer and marketer of electronic products for managing forklifts, construction vehicles, and other industrial equipment; terms not disclosed (IDSY) : In 2016, Keytroller generated $6.6 million in revenue and net income of $1.5 million. Keytroller has achieved impartial annual revenue growth of more than 25% per year over the past three years.

    9:08 am Procter & Gamble files proxy statement w/ SEC; 'expects to drive 2% to 3% organic sales growth in fiscal 2018', reaffirms expectations for core earnings per share growth of 5% to 7% (PG) :  

    9:07 am Bank of Princeton commences trading on Nasdaq, prices underwritten public offering of 1.5 mln shares of its common stock at a charge to the public of $32/share (BPRN) : The Bank of Princeton intends to expend the proceeds for generic corporate purposes, additional organic growth through its loan portfolio or through strategic acquisitions, financings, investments, and capital expenditures.

    9:04 am Fiat Chrysler reports July US sales -10% y/y to 161477 units and retail sales -6% y/y to 145,391 units (FCAU) :

  • In line with FCA's strategy to reduce sales to the daily rental segment, fleet sales of 16,086 units were down, as expected, 35 percent year over year.
  • 9:03 am Scripps has acquired the Katz broadcast networks, which deal programming for targeted audiences over the air, in a deal worth $302 million (SSP) :

    Scripps intends to finance the transaction with $250 million of novel debt and about $50 million of cash on hand. Upon closing, Scripps' leverage is expected to exist about 3x on a pro forma 2017/18 blended basis.

  • At June 30, 2017, Scripps had $150 million of cash on its poise sheet and unfunded revolver commitments of $125 million.
  • The four national networks, Bounce, Grit, evade and Laff each gain more than 80 percent of sum U.S. households and 'are among the fastest-growing in television today.'
  • The four networks are forecast to generate about $180 million in revenue and about $30 million in segment profit in 2018. The transaction is expected to exist accretive to Scripps' earnings in 2018 and beyond.
  • 9:02 am Cree reaches settlement in its patent infringement lawsuit with E. Mishan and Sons; 'Emson has agreed to an exclusive supply agreement to purchase market leading Cree high power LEDs for its high performance tactical flashlights ' (CREE) :  

    9:02 am Skyline Medical signs binding note of intent for a merger transaction with privately held biomedical company CytoBioscience (SKLN) :

    CytoBioscience creates and manufactures devices used in human cell research focused on novel therapeutic drug evolution and has a well-known scientific and technical staff, collaborative partnerships with leading pharmaceutical companies and strategic alliances with key groups and academic institutions. CytoBioscience has reported a current backlog of $6 million in orders and anticipated condense research work.

  • The merger is expected to close by September 30, 2017.
  • 8:50 am S&P futures vs honest value: +7.80. Nasdaq futures vs honest value: +20.90. (:WRAPX) :

    The S&P 500 futures trade eight points, or 0.3%, above honest value.

    Equity indices in the Asia-Pacific region ended Tuesday on a higher note. Regional economic data included below-consensus Manufacturing PMI readings from India and Japan while China's Caixin Manufacturing PMI beat expectations. The People's Bank of China reportedly uncovered operational violations at 40 Chinese banks. The banks maintain up to six months to correct the issues. In Japan, Chief Cabinet Secretary Yoshihide Suga confirmed that Prime Minister Shinzo Abe plans to reshuffle his cabinet on August 3. The Reserve Bank of Australia left its cash rate unchanged at 1.50%, as expected. The central bank notable that the relative energy of the Australian dollar results from weakness in the U.S. dollar. The Reserve Bank of India will meet overnight.

  • In economic data:
  • Japan's July Manufacturing PMI 52.1 (expected 52.2; terminal 52.2)
  • China's July Caixin Manufacturing PMI 51.1 (consensus 50.4; terminal 50.4)
  • India's Nikkei July Manufacturing PMI 47.9 (expected 50.8; terminal 50.9)
  • South Korea's July Nikkei Manufacturing PMI 49.1 (last 50.1)
  • Australia's July AIG Manufacturing Index 56.0 (last 55.0)
  • South Korea's July CPI +0.2% month-over-month (last -0.1%); +1.9% year-over-year (consensus 2.0%; terminal 1.9%). July trade surplus narrowed to KRW10.65 billion from KRW10.77 billion. July Imports +14.5% year-over-year (last 19.8%) and July Exports +19.5% year-over-year (last 13.6%)
  • ---Equity Markets---

  • Japan's Nikkei edged up 0.3%. Toshiba spiked 11.0% while Nitto Denko, Yamato Holdings, Teijin, Sumitomo Mitsui Financial, T&D Holdings, Dentsu, Sumitomo Mitsui, Sony pecuniary Holdings, and Mitsubishi advanced between 1.8% and 3.7%.
  • Hong Kong's Hang Seng climbed 0.8%, nearing its high from 2015. Financials ended in the lead with Ping An Insurance, China Life Insurance, BoC Hong Kong, Bank of China, Bank of East Asia, China Construction Bank, ICBC, and Hang Seng Bank climbed between 0.8% and 4.1%. On the downside, Geely Automobile lost 1.8%.
  • China's Shanghai Composite slipped from its high in afternoon action, but charged to a fresh high into the close, adding 0.6%. Shanghai Jin Jiang International Industrial Investment, Shanghai Lujiazui Finance & Trade Zone Development, Anhui Expressway, Bestsun Energy, and Beijing Teamsun Technology gained between 4.5% and 5.1%.
  • India's Sensex ticked up 0.2% with more than half of its components moving higher. Hero MotoCorp, Maruti Suzuki, and Mahidra&Mahindra gained between 1.8% and 2.1% while tech consultants were mixed. Wipro gained 1.8%, Tata Consultancy shed 0.2%, and Infosys lost 0.6%. Lupin was the weakest performer, falling 1.4%.
  • Major European indices trade higher across the board while the euro (1.1810) has shed 0.3% against the dollar after hitting a 19-month high against the greenback yesterday afternoon. British Chancellor Philip Hammond said Brexit will not exist postponed or delayed, but the balancing of the UK's budget may exist delayed.

  • In economic data:
  • Eurozone Q2 GDP +0.6% quarter-over-quarter, as expected (last 0.5%); +2.1% year-over-year (consensus 2.4%; terminal 1.9%). July Manufacturing PMI 56.6 (expected 56.8; terminal 56.8)
  • Germany's July Manufacturing PMI 58.1 (expected 58.3; terminal 58.3). July Unemployment Change -9,000 (consensus -5,000; terminal 6,000) and Unemployment Rate held at 5.7%, as expected
  • UK's July Manufacturing PMI 55.1 (expected 54.4; terminal 54.2). July Nationwide HPI +0.3% month-over-month (expected -0.1%; terminal 1.1%); +2.9% year-over-year (consensus 2.7%; terminal 3.1%)
  • France's July Manufacturing PMI 54.9 (expected 55.4; terminal 55.4)
  • Italy's July Manufacturing PMI 55.1 (consensus 55.2; terminal 55.2)
  • Spain's July Manufacturing PMI 54.0 (expected 54.5; terminal 54.7)
  • ---Equity Markets---

  • Germany's DAX is higher by 0.7% with most components trading in the green. Lufthansa has spiked 2.6% while Prosiebensat 1, Heidelbergcement, and Infineon are up between 1.5% and 1.7%. BMW, Daimler, and Volkswagen demonstrate gains between 0.8% and 1.5%. Adidas is the weakest component, falling 0.9%.
  • France's CAC trades up 0.7% with heavyweights among the leaders. Peugeot, Airbus Group, Renault, Louis Vuitton, and Total maintain added between 1.3% and 1.8%. A handful of consumer names lag with Danone and Pernod Ricard shedding 0.4% and 0.6%, respectively.
  • UK's FTSE has climbed 0.8%. Rolls-Royce has surged 9.6% in reaction to upbeat earnings while BP has climbed 3.2% after it too beat estimates. Consumer stocks dote Paddy Power, Imperial Brands, Taylor Wimpey, Burberry, and British American Tobacco demonstrate gains between 1.4% and 2.0%. On the downside, select miners dote Fresnillo, Anglo American, and Randgold Resources demonstrate losses between 0.4% and 2.4%.
  • 8:47 am On The Wires (:WIRES) :

  • Cellectar Biosciences (CLRB) initiates a collaboration with Avicenna Oncology GmbH, a precision medicine company based in Basel, Switzerland. The collaboration will focus on the evolution of novel phospholipid drug conjugates combining Cellectar's patented phospholipid ether delivery platform with Avicenna's novel cytotoxic payloads.
  • AstroNova (ALOT) has been selected by one of Latin America's Top 10 airlines to provide their ToughWriter 640 narrow format flight deck printer for its future fleet of Boeing 737 MAX aircraft.
  • Oshkosh (OSK) announced that the U.S. Army has placed another order for the Joint Light Tactical Vehicle (:JLTV) program including 748 vehicles and 2,359 installed and packaged kits. The order valued at more than $195 million, is the fifth order for JLTVs since the condense was awarded in August 2015.
  • Catasys (CATS) expanded its OnTrak-A program with one of the 'nation's leading health insurance providers' to now comprise anxiety in three states: Illinois, Kansas and Missouri.
  • 8:46 am Aspen Group approved for listing on the Nasdaq Capital Market efficient Wednesday, August 2 (ASPU) :  

    8:45 am European Summary (BONDX) :

    Core Yields Inch Lower

  • The first half of the European session has been underscored by slim gains in core debt. Today's modest gains arrive after nearly a week of sideways action. The euro has shed 0.3% to 1.1810 against the U.S. dollar after hitting a 19-month high yesterday. British Chancellor Philip Hammond pushed back against suggestions that Brexit may exist delayed or postponed. European economic data showed mostly disappointing revisions to Manufacturing PMI readings, but the figures remained in expansion despite pulling back.
  • Economic Data:
  • Eurozone Q2 GDP +0.6% quarter-over-quarter, as expected (last 0.5%); +2.1% year-over-year (consensus 2.4%; terminal 1.9%). July Manufacturing PMI 56.6 (expected 56.8; terminal 56.8)
  • Germany's July Manufacturing PMI 58.1 (expected 58.3; terminal 58.3). July Unemployment Change -9,000 (consensus -5,000; terminal 6,000) and Unemployment Rate held at 5.7%, as expected
  • UK's July Manufacturing PMI 55.1 (expected 54.4; terminal 54.2). July Nationwide HPI +0.3% month-over-month (expected -0.1%; terminal 1.1%); +2.9% year-over-year (consensus 2.7%; terminal 3.1%)
  • France's July Manufacturing PMI 54.9 (expected 55.4; terminal 55.4)
  • Italy's July Manufacturing PMI 55.1 (consensus 55.2; terminal 55.2)
  • Spain's July Manufacturing PMI 54.0 (expected 54.5; terminal 54.7)
  • New Issuance:
  • Germany sold EUR3.20 billion of 2-year Schatz bonds at a capitulate of -0.63% with a bid-to-cover of 2.0
  • UK's GBP2.25 billion 10-yr gilt reopening drew a capitulate of 1.267% with a bid-to-cover of 2.56
  • Yield Check:
  • France, 10-yr OAT: -1 bp to 0.79%
  • Germany, 10-yr bund: -1 bp to 0.52%
  • Greece, 10-yr note: +1 bp to 5.21%
  • Italy, 10-yr BTP: -1 bp to 2.08%
  • Portugal, 10-yr PGB: +1 bp to 2.87%
  • Spain, 10-yr ODE: UNCH at 1.49%
  • U.K., 10-yr gilt: +1 bp to 1.24%
  • 8:36 am National Retail Properties beats by $0.02, beats on revs; raises FY17 core FFO guidance (NNN) :

  • Reports Q2 (Jun) core FFO of $0.64 per share, $0.02 better than the Capital IQ Consensus of $0.62; revenues rose 11.2% year/year to $145.55 mln vs the $142.83 mln Capital IQ Consensus. AFFO for Q2 was $0.65 per share.
  • Co issues in-line guidance for FY17, sees core FFO of $2.46-2.50, excluding non-recurring items, vs. $2.48 Capital IQ Consensus assess and vs prior guidance of $2.44-2.48. AFFO for 2017 is expected to exist $2.50-2.54.
  • "National Retail Properties enjoyed another impressive quarter, driven by their robust portfolio, their selectively underwritten acquisitions, and their flexible, low leverage poise sheet, sum of which has positioned us to raise their guidance and, as previously announced, to raise their common dividend for the 28th consecutive year, a record matched by only three other REITs and less than 90 public companies in the United States."
  • 8:34 am S&P futures vs honest value: +6.00. Nasdaq futures vs honest value: +19.80. (:WRAPX) :

    The S&P 500 futures currently trade six points, or 0.2%, above honest value.

    Just in, personal income was unchanged in June (Briefing.com consensus +0.3%) after a downwardly revised 0.3% extend for May (from 0.4%). Personal spending rose 0.1%, as expected, while the prior month's reading was revised to 0.2% from 0.1%.

    The core PCE charge Index, which excludes food and energy, increased 0.1%, as expected.

    8:33 am Cerus signs two, new, expanded contracts with tablissement Franais du Sang, the French National Blood Service, for the INTERCEPT Blood System (CERS) : One condense covers the supply of INTERCEPT Platelet kits while the other is for the purchase of additional Illuminators to abet uphold the roll-out to novel regions. The initial term of this platelet kit supply agreement is two years with two one-year extension options, supporting INTERCEPT platelet production in sum EFS regional centers.

    8:33 am Simon Properties beats by $0.03, reports revs in-line; guides FY17 FFO in-line (SPG) :

  • Reports Q2 (Jun) funds from operations of $2.47 per share, $0.03 better than the Capital IQ Consensus of $2.44; revenues rose 3.5% year/year to $1.36 bln vs the $1.37 bln Capital IQ Consensus
  • Growth in comparable FFO per diluted share for the three months ended June 30, 2017 was 7.6%
  • Total portfolio NOI growth for the three months ended June 30, 2017 was 5.0% and was 5.3% for the six months ended June 30, 2017
  • Co issues in-line guidance for FY17, sees FFO of $11.14-11.22 vs. $11.21 Capital IQ Consensus Estimate.
  • 8:32 am Cidara Therapeutics announces publication of data, in the journal Antimicrobial Agents and Chemotherapy, from an in vivo study investigating the deep tissue distribution of CD101 compared tomicafungin in the setting of intra-abdominal candidiasis (CDTX) :

    The study is the first to expend MALDI-MS imaging, a powerful tool that enables investigators to acquire molecular information about drug distributions in tissues, as well as drug quantification methods, in a clinically relevant mouse intra-abdominal abscesses model.

  • Results demonstrate that CD101 had a dose-dependent four-to-six-fold superior penetration into infectious lesions days after the solitary CD101 dose as compared to daily micafungin.
  • CD101 accumulated at levels that would exist expected to forestall mutations leading to antifungal resistance.
  • "The in vivo data published in AAC verify the potential of CD101 as a future treatment option for patients with IAC because of the extraordinary tissue penetration at the site of infection." said David Perlin, Ph.D., executive director and professor, PHRI.
  • 8:31 am Sientra enters a settlement agreement regarding mutual IP ownership and condense disputes with its former breast implant condense manufacturer, Silimed-Indstria de Implantes; co to pay $10 mln and up to $5 mln in royalty payments (SIEN) :

    The settlement resolves sum claims that the parties filed against each other, and clears the path for Sientra to execute on its going-forward plans, unencumbered and undistracted by these disputes.

  • The Company has furthermore agreed to pay Silimed a lump sum of $9,000,000 within 30-days of execution of the Settlement Agreement, and $1,000,000 on or by July 1, 2018.
  • In addition, should the Company enter into international markets using inevitable breast implant specifications, the Company has agreed to compose royalty payments of $12.50 on its net sales of such products, up to a maximum royalty of $5,000,000.
  • The Settlement Agreement was a compromise and settlement of disputed claims between the parties and not an admission of liability which was expressly denied.
  • 8:31 am Medovex reports initial results from the first cases conducted in Germany for the DenerveX System; 'excellent initial success' (MDVX) :

  • Dr. Martin Deeg stated, "Both of the first two DenerveX System cases met with what I reckon excellent initial success. Both patients experienced initial smart reduction of the Facet Joint during the actual running of the device. Additionally, both patients walked out of the procedure play on their own power and were discharged shortly following the procedure."
  • Case One: Female, 40 years old, L4, two joints treated. Patient had injection local only at the facet joint. At the discontinue of the procedure the patient moved herself from the table and walked under her own power out of the procedure play and was discharged shortly after with no smart prescription provided other than over the counter smart relief medicines.
  • Case Two: Male, 42 year old, L5, two joints treated. Patient had an injected local only at the facet joint. At the discontinue of the procedure the patient moved from the table and walked out of the procedure play on their own power and was discharged shortly after, again no smart relief prescriptions provided only over the counter medicines recommended.
  • 8:27 am On The Wires (:WIRES) :

  • Workhorse (WKHS) announced that Brink's (BCO) has purchased two Workhorse Class 5 E-GEN and E-100 chassis, paired with a Brink's custom logistics body. The E-100 all-electric truck and the E-GEN electric extended-range truck will exist deployed in California and Chicago to enhance the Brink's U.S. fleet with cleaner, more economic vehicles.
  • WPP (WPPGY) announces that tenthavenue, its global out of home media and experiential marketing division, is investing in LOOM Media, a US-based start-up company specializing in creating opportunities for brands to sponsor urban innovation.
  • ParkerVision, Inc. (PRKR) will originate taking orders for Milo, its novel distributed Wi-Fi system for consumers, by the middle of August. Milo will initially exist available for purchase at Amazon.com, as well as the Milo online store at milowifi.com.
  • Acceleron (XLRN) announced that the first patient has been treated in a side 2 clinical affliction of ACE-083, the Company's locally acting muscle agent, for the treatment of patients with Charcot-Marie-Tooth disease (CMT), a commonly inherited neurological disease leading to focal muscle weakness. The side 2 affliction in CMT expands wholly-owned ACE-083 program and muscle franchise into novel region of high unmet medical need
  • 8:19 am Ecolab beats by $0.01, beats on revs; guides Q3 EPS in-line; reaffirms FY17 EPS guidance (ECL) :

  • Reports Q2 (Jun) earnings of $1.13 per share, excluding non-recurring items, $0.01 better than the Capital IQ Consensus of $1.12; revenues rose 4.4% year/year to $3.46 bln vs the $3.40 bln Capital IQ Consensus.
  • Co issues in-line guidance for Q3, sees EPS of $1.36-1.44, excluding non-recurring items, vs. $1.42 Capital IQ Consensus Estimate.
  • Co reaffirms guidance for FY17, sees EPS of $4.70-4.90, excluding non-recurring items, vs. $4.79 Capital IQ Consensus Estimate.
  • "Our business is improving and they remain positioned to deliver estimable results for the year. [Q2] results were as expected, with their Institutional, Industrial and Other segments showing continued sales acceleration and their Energy segment sales moved to growth. Their operating income was virtually flat with terminal year as sum of their estimable drudgery driving sales, pricing and cost savings were largely offset by higher delivered product costs including a currency hedging headwind."
  • "We already maintain solid novel business and pricing momentum across sum of their segments. In addition, they await delivered product costs including hedging to exist less of a year-on-year headwind in the second half...In total, they forecast a stalwart second half delivering a estimable 2017, and await to exit the year with excellent momentum moving into 2018."
  • 8:16 am ManTech receives a multi-year award IDIQ condense with a total ceiling value of $200 million to provide uphold for Defense Advanced Research Projects Agency's Scientific, Engineering, and Technical Assistance program (MANT) :  

    8:14 am Royal Caribbean beats by $0.04, reports revs in-line; guides Q3 EPS above consensus; guides FY17 EPS above consensus (RCL) :

  • Reports Q2 (Jun) earnings of $1.71 per share, $0.04 better than the Capital IQ Consensus of $1.67 and above prior guidance of $1.60-1.65; revenues rose 4.3% year/year to $2.20 bln vs the $2.19 bln Capital IQ Consensus.
  • Co issues upside guidance for Q3, sees EPS of approx $3.45, excluding non-recurring items, vs. $3.30 Capital IQ Consensus Estimate.
  • Co issues upside guidance for FY17, sees EPS of approx $7.35-7.45, excluding non-recurring items, vs. $7.25 Capital IQ Consensus assess and vs prior guidance of $7.00-7.20.
  • "Our brands are executing beautifully, keeping the business in an exceptionally stalwart position...Strong close-in claim for cruise bolstered the quarter, and they behold further uplift for the poise of the year, positioning us well for the Double-Double and beyond."
  • Gross Yields were up 10.2% on a Constant-Currency basis. Net Yields on a Constant-Currency basis increased 11.5%, exceeding prior guidance due to stalwart close-in claim driving higher pricing and occupancy.
  • 8:14 am Vertex Pharma announces that the FDA has approved KALYDECO (ivacaftor) for expend in more than 600 people with cystic fibrosis; increases guidance for KALYDECO product revenues (VRTX) :

  • This approval was based on side 3 clinical data for KALYDECO in these mutations and follows the FDA's approval of KALYDECO in May 2017 for 23 other residual role mutations, which was based on analyses of in vitro data. Both approvals are supported by more than five years of real-world clinical relish that demonstrate KALYDECO's established safety and efficacy profile.
  • Based on today's approval, Vertex increased its guidance for 2017 KALYDECO product revenues to a gain of $770 million to $800 million (prior: $740 to $770 million).
  • Vertex's guidance gain for total CF product revenues in 2017 is now $1.87 billion to $2.1 billion (prior: $1.84-$2.07 billion), including ORKAMBI guidance of $1.1 billion - $1.3 billion (prior: $1.1-1.3 billion). 
  • "In the five years since KALYDECO became the first approved medicine to treat the underlying judgement of cystic fibrosis, they maintain been relentless in their efforts to bring this Important medicine to sum who may benefit," said Jeffrey Chodakewitz, M.D., Executive Vice President and Chief Medical Officer at Vertex. "We will continue to pursue this goal until sum people with CF maintain a medicine that treats their form of this sober and life-shortening disease."
  • 8:11 am Overnight Treasury Market Summary (BONDX) :

    Little Changed Once Again

  • U.S. Treasuries maintain spent the night inside a narrow range, which leaves the market on track for a flat start. However, some movement is expected to result the 8:30 ET release of June Personal Income (Briefing.com consensus 0.3%), Personal Spending (Briefing.com consensus 0.1%), and core PCE Prices (Briefing.com consensus 0.1%). Treasuries held their ground overnight, showing itsy-bitsy reaction to Asian economic data, which showed below-consensus Manufacturing PMI readings from Japan and India while China's Caixin Manufacturing PMI beat expectations after the official reading missed estimates on Monday. The Reserve Bank of Australia held its cash rate at 1.50%, as expected. The central bank's statement notable that energy of the Australian dollar is mostly due to the underperformance of the greenback. The S&P 500 futures trade five points above honest value while raw oil is down 0.6% at $49.89/bbl. The Dollar Index is up 0.1% after ending yesterday's session at its lowest flush since May 2016.
  • Yield Check:
  • 2-yr: UNCH at 1.36%
  • 5-yr: +1 bp to 1.84%
  • 10-yr: UNCH at 2.30%
  • 30-yr: UNCH at 2.90%
  • International News:
  • Japan's July Manufacturing PMI 52.1 (expected 52.2; terminal 52.2)
  • China's July Caixin Manufacturing PMI 51.1 (consensus 50.4; terminal 50.4)
  • India's Nikkei July Manufacturing PMI 47.9 (expected 50.8; terminal 50.9)
  • South Korea's July Nikkei Manufacturing PMI 49.1 (last 50.1) Australia's July AIG Manufacturing Index 56.0 (last 55.0) South Korea's July CPI +0.2% month-over-month (last -0.1%); +1.9% year-over-year (consensus 2.0%; terminal 1.9%). July trade surplus narrowed to KRW10.65 billion from KRW10.77 billion. July Imports +14.5% year-over-year (last 19.8%) and July Exports +19.5% year-over-year (last 13.6%)
  • Eurozone Q2 GDP +0.6% quarter-over-quarter, as expected (last 0.5%); +2.1% year-over-year (consensus 2.4%; terminal 1.9%). July Manufacturing PMI 56.6 (expected 56.8; terminal 56.8)
  • Germany's July Manufacturing PMI 58.1 (expected 58.3; terminal 58.3). July Unemployment Change -9,000 (consensus -5,000; terminal 6,000) and Unemployment Rate held at 5.7%, as expected
  • Data out Today:
  • June Personal Income (Briefing.com consensus 0.3%), Personal Spending (Briefing.com consensus 0.1%), core PCE Prices (Briefing.com consensus 0.1%) at 8:30 ET
  • June Construction Spending (Briefing.com consensus 0.5%) at 10:00 ET
  • July ISM Index (Briefing.com consensus 56.2) at 10:00 ET July auto and truck sales reported throughout the day
  • 8:11 am Precipio to tender for sale its common stock and warrants in an underwritten public offering; size not disclosed (PRPO) : The Company intends to expend the net proceeds from this offering for the repayment of debt, growth of its sales force, progression of its product evolution and for working capital and generic corporate purposes.

    8:10 am HCP beats by $0.01, reports revs in-line; reaffirms FY17 FFO guidance in-line (HCP) :

  • Reports Q2 (Jun) funds from operations of $0.48 per share, $0.01 better than the Capital IQ Consensus of $0.47; revenues fell 14.8% year/year to $458.9 mln vs the $456.29 mln Capital IQ Consensus.
  • Co reaffirms guidance for FY17, sees FFO of $1.89-1.95 vs. $1.94 Capital IQ Consensus Estimate
  • In addition, co expects 2017 SPP Cash NOI to extend between 2.5-3.5%
  • Tandem debt investment update:

  • During the second quarter, continued challenges in the post-acute/skilled nursing operating environment and tenant-specific headwinds contributed to a decline in the pecuniary performance of the assets underlying their Tandem debt investment
  • "As a result, the honest value of their collateral, net of the senior mortgage debt, fell below the carrying value of their investment. As Part of their quarterly review process, they recorded a $57 million impairment write-down during the second quarter and reduced the carrying value of their Tandem debt investment to $200 million"
  • "On July 31, subsequent to the aforementioned impairment, they entered into a definitive agreement to sell their Tandem debt investment for $197 million, theme to customary closing conditions. This investment represents their terminal meaningful exposure to both post-acute/skilled-nursing assets and highly-leveraged mezzanine investments. The transaction is expected to close during 2017"
  • 8:09 am Independence Realty faith beats by $0.01, reports revs in-line; guides FY17 FFO in-line (IRT) :

  • Reports Q2 (Jun) funds from operations of $0.19 per share, $0.01 better than the Capital IQ Consensus of $0.18; revenues rose 2.9% year/year to $39.43 mln vs the $39.43 mln Capital IQ Consensus.
  • Co issues in-line guidance for FY17, sees FFO of $0.73-0.76 vs. $0.74 Capital IQ Consensus Estimate.
  • 8:07 am athenaHealth announces a 'comprehensive review of its operations, cost structure and capital allocation'; has identified approx. $100 mln in cost-savings opportunities and to part chairman and CEO role (ATHN) :

    In conducting its review, athenahealth has identified ~$100 million in cost-savings opportunities 'that will drive efficiency and targeted investment in the Company's hospital and network services businesses.'

  • athenahealth will provide additional information regarding details of these strategic initiatives, including plans to significantly extend operating margins, in 2018 and thereafter, by its 3Q17 earnings release anticipated in October 2017.
  • athenahealth furthermore intends to establish the role of president.

  • The Board has retained a leading search solid to fill the president and CFO roles promptly.
  • The Board plans to part the roles of chairman and CEO and is working to recruit an independent chairman.

  • In addition, the Board has begun a search process to nominate an additional independent director.
  • 8:07 am Meritage beats by $0.22, beats on revs; raises revenue guidance (MTH) :

  • Reports Q2 (Jun) earnings of $0.98 per share, $0.22 better than the Capital IQ Consensus of $0.76; revenues rose 0.5% year/year to $802 mln vs the $760.39 mln Capital IQ Consensus. Home closing revenue was consistent with the prior year, as a 3% extend in impartial closing charge offset a 2% diminish in home closings compared to the second quarter of 2016. The West and Central regions delivered year-over-year increases of 11% and 9% in home closing revenue, respectively, reflecting stalwart growth in Arizona and Texas. A 21% decline in East region home closing revenue reflected lower orders over the terminal three quarters as the region was going through a product library upgrade which delayed the openings of a number of communities.
  • Total orders for the second quarter increased 4% year-over-year due to stalwart claim in the West and Central regions. Orders increased 30% over the second quarter of 2016 in Texas, as a result of a 24% extend in impartial energetic communities during the quarter and a 5% extend in absorptions (orders per impartial energetic community). Orders increased 2% in the West on a 4% extend in absorptions that was mostly offset by a 3% decline in impartial community count. East region orders were down 13% compared to the prior year's second quarter, primarily due to a 12% decline in absorptions. Home closing indecorous margin was 17.7% for the second quarter of 2017, compared to 17.3% in the second quarter of 2016. The margin improvement reflects increases in home prices that generally offset increases in land and construction costs, as well as improved leverage of construction overhead expenses.
  • "Housing market conditions remain robust and Meritage is well-positioned in many of the best markets. They believe that claim for novel homes will continue to exist strong, and they are prepared to engage advantage of it," Mr. Hilton concluded. "We are on track to deliver approximately 7,600-8,000 homes and generate estimated total closing revenue of $3.2-3.4 billion for the year (up from $3.1-3.2 bln vs. $3.27 bln consensus). They anticipate pricing power in most markets will allow us to maintain indecorous margins consistent with 2016 while generating ~$230-250 million in pre-tax earnings through a combination of cost management and operating leverage with their anticipated revenue growth."
  • 8:07 am GenMark Diagnostics misses by $0.05, reports revs in-line (GNMK) :

  • Reports Q2 (Jun) loss of $0.37 per share, $0.05 worse than the Capital IQ Consensus of ($0.32); revenues fell 1.2% year/year to $12.36 mln vs the $12.44 mln Capital IQ Consensus.
  • "We are delighted to maintain accomplished several Important goals in the second quarter. Their team achieved FDA 510(k) clearance of the ePlex instrument and Respiratory Pathogen Panel as well as CE designate for sum three of their Blood Culture ID Panels," said Hany Massarany, President and Chief Executive Officer of GenMark. "In addition, they significantly strengthened their poise sheet, which will enable us to bring even more focus to the global commercialization of their ePlex System and its menu expansion," added Massarany.
  • 8:05 am Bayer AG and Rothamsted Research symptom strategic framework agreement (BAYRY) :

  • Cos maintain entered into a strategic framework agreement to better collaborations in scientific areas that will uphold the evolution of more customized agronomic solutions for farmers.
  • Building on a track record of collaborations, the partners are forming this strategic alliance to uphold a digital revolution for detecting and managing biotic threats such as pests, pathogens and weeds more sustainably. Co-ordinated activities, in the laboratory and in the field, will generate the data, know-how, tools and technologies that abet to uphold a transition to smarter crop protection.
  • 8:05 am LogMeIn acquires Nanorep sum of the outstanding equity interests in Nanorep for a purchase charge of approximately $45 million; NanoRep is a digital self-service, chatbot and virtual coadjutant company (LOGM) : Headquartered in Herzliya, Israel, Nanorep harnesses synthetic intelligence and patented natural language processing technologies to create solutions that compose self-service more engaging and intuitive. LogMeIn is furthermore expected to pay up to $5 million in contingent cash payments to inevitable continuing employees of Nanorep upon their achievement of milestone and retention targets over the two-year epoch following the closing of the transaction.

    8:05 am Fiserv acquires the assets of PCLender, a provider of enterprise internet-based mortgage software and mortgage lending technology solutions; terms not disclosed (FISV) :  

    8:04 am Nant Health: Blue Cross and Blue Shield of Nebraska has signed a three-year condense extension for NaviNet Open (NH) :  

    8:04 am American Railcar Industries misses by $0.04, misses on revs (ARII) :

  • Reports Q2 (Jun) earnings of $0.57 per share, $0.04 worse than the Capital IQ Consensus of $0.61; revenues fell 27.6% year/year to $109 mln vs the $113.62 mln Capital IQ Consensus
  • This diminish was due to decreased revenues in the manufacturing segment, partially offset by slightly increased revenues in the railcar leasing and railcar services segments
  • Lease fleet reaches 12,414 railcars as of June 30, 2017 vs. 10,641 railcars as of June 30, 2016, with 545 railcars added during the second quarter
  • ARI's backlog as of June 30, 2017 was 2,878 railcars with an estimated market value of $270.0 million. Of the total backlog, co currently await 715 railcars, or 25%, having an estimated market value of $66.5 million, will exist placed into their lease fleet.
  • 8:03 am Insperity beats by $0.14, beats on revs; guides Q3 EPS below consensus; guides FY17 EPS above consensus (NSP) :

  • Reports Q2 (Jun) earnings of $0.82 per share, excluding non-recurring items, $0.14 better than the Capital IQ Consensus of $0.68; revenues rose 12.5% year/year to $795.5 mln vs the $778.88 mln Capital IQ Consensus. Adjusted EBITDA increased 30% over the second quarter of 2016 to $33.3 million.
  • Co issues downside guidance for Q3, sees EPS of $0.94-1.00, excluding non-recurring items, vs. $1.02 Capital IQ Consensus Estimate.
  • Co issues raised guidance for FY17, sees EPS of $4.47-4.60 from $4.30-4.44, excluding non-recurring items, vs. $4.33 Capital IQ Consensus Estimate.
  • 8:02 am ProAssurance sees prelim Q2 $0.38-0.41 vs $0.54 Capital IQ Consensus assess (PRA) :  Co states, "We believe indecorous premiums written in the quarter will exist approximately $206.0 million and net earned premium for the quarter will exist approximately $180.5 million. They anticipate favorable loss evolution will exist in the gain of $28.5 million to $30.0 million and they project their consolidated combined ratio to exist in a gain between 95% and 97% for the quarter."

    8:02 am Sabre reports EPS in-line, revs in-line; reaffirms FY17 EPS and revenue guidance but now expects EPS to exist in lower half of guidance; announces reorganization, 9% headcount reduction (SABR) :

  • Reports Q2 (Jun) earnings of $0.35 per share, excluding non-recurring items, in-line with the Capital IQ Consensus of $0.35; revenues rose 6.6% year/year to $900.7 mln vs the $895.1 mln Capital IQ Consensus.
  • Co reaffirms guidance for FY17, sees EPS of $1.31-1.45, excluding non-recurring items, vs. $1.39 Capital IQ Consensus Estimate; sees FY17 revs of $3.54-3.62 bln vs. $3.58 bln Capital IQ Consensus Estimate. However, Sabre now expects that 2017 EPS results will likely exist in the lower half of this guidance. Strategic prioritization has led Sabre to reduce its expectations for 2017 cap-ex and capitalized implementation costs by $50 million in aggregate.
  • Co announces an initiative to streamline and focus the business through reorganizing inevitable functions, reducing layers of management, and lowering costs to enable a more nimble, faster moving and focused organization. The initiative is expected to reduce global headcount by approximately 9%. At complete run-rate, the program is anticipated to result in approximately $110 mln of annual savings. Sabre expects the program to exist neutral to 2017 Free Cash Flow. Cost savings under the initiative are expected to achieve complete run-rate in 2018.
  • 8:02 am IPG Photonics beats by $0.26, beats on revs; guides Q3 EPS above consensus, revs above consensus (IPGP) :

  • Reports Q2 (Jun) earnings of $1.91 per share, $0.26 better than the Capital IQ Consensus of $1.65; revenues rose 46.1% year/year to $369.37 mln vs the $333.06 mln Capital IQ Consensus.
  • Co issues upside guidance for Q3, sees EPS of $1.70-1.90 vs. $1.59 Capital IQ Consensus Estimate; sees Q3 revs of $350-375 mln vs. $318.62 mln Capital IQ Consensus Estimate.
  • Demand for their core products, particularly high-power, kilowatt-scale fiber lasers, has never been stronger. Their leadership position within this fast-growing market drove record order activity in the quarter, resulting in a book-to-bill ratio above one. Based on these trends and the energy of their current backlog, they believe they are in excellent position to deliver another stalwart quarter in three months
  • Year-to-date bookings maintain exceeded their expectations, pointing to stalwart revenue growth in 2017. Based on first half outperformance and current backlog, they are now targeting approximately 32% to 34% revenue growth for the complete year. Their fourth quarter performance will exist driven by order activity through the discontinue of the third quarter and during the fourth quarter, for which their visibility is low. Given the magnitude of outperformance during the first half of the year, they believe it is prudent to assume a lower growth rate in the fourth quarter due to more challenging comparisons and an expected slowdown in spending related to typical seasonality in China and the consumer electronics investment cycle. Should this anticipated spending slowdown fail to materialize at a flush consistent with historic trends, this could result in upside to their complete year guidance range
  • 8:01 am S&P futures vs honest value: +5.30. Nasdaq futures vs honest value: +20.40. (:WRAPX) :

    It appears that the stock market will open Tuesday's session in the green following yesterday's mixed finish. The S&P 500 futures currently trade five points, or 0.2%, above honest value.

    Apple (AAPL 149.00, +0.27), the S&P 500's largest component by market cap, will release its latest earnings report following today's closing bell. Investors will exist looking for further details on the much-anticipated iPhone 8, which is expected to exist released later this year. AAPL shares currently hold a year-to-date gain of 28.4%.

    The Personal Income and Personal Spending Report for June, which will cross the wires at 8:30 ET, is the highlight on today's economic calendar. The Briefing.com consensus expects that personal income and personal spending will extend by 0.3% and 0.1%, respectively. The report will furthermore comprise the core PCE charge Index (Briefing.com consensus 0.1%).

    In addition, investors will furthermore receive the June Construction Spending Report (Briefing.com consensus 0.5%) and the July ISM Index (Briefing.com consensus 56.2), both of which will exist released at 10:00 ET. Auto and truck sales will exist released throughout the day.

    U.S. Treasuries are trading flat for the second day in a row, leaving the benchmark 10-yr capitulate unchanged at 2.29%. Meanwhile, the U.S. Dollar Index (92.82, +0.15) is up 0.2% and raw oil is down 0.4% at $49.98/bbl. The commodity enters today's session on a six-session winning streak. 

    In U.S. corporate news:

  • Pfizer (PFE 33.38, +0.22): +0.7% after better than expected earnings outweighed lower than expected revenues.
  • Sprint (S 8.20, +0.22): +2.8% after beating bottom-line estimates and raising its profit guidance.
  • Under Armour (UAA 19.61, -0.41): -2.1% after downbeat guidance overshadowed better than expected earnings and revenues.
  • Reviewing overnight developments:

  • Equity indices in the Asia-Pacific region ended Tuesday on a higher note. Japan's Nikkei +0.3%, Hong Kong's Hang Seng +0.8%, China's Shanghai Composite +0.6%, India's Sensex +0.2%.
  • In economic data:
  • Japan's July Manufacturing PMI 52.1 (expected 52.2; terminal 52.2)
  • China's July Caixin Manufacturing PMI 51.1 (consensus 50.4; terminal 50.4)
  • India's Nikkei July Manufacturing PMI 47.9 (expected 50.8; terminal 50.9)
  • South Korea's July Nikkei Manufacturing PMI 49.1 (last 50.1)
  • Australia's July AIG Manufacturing Index 56.0 (last 55.0)
  • South Korea's July CPI +0.2% month-over-month (last -0.1%); +1.9% year-over-year (consensus 2.0%; terminal 1.9%). July trade surplus narrowed to KRW10.65 billion from KRW10.77 billion. July Imports +14.5% year-over-year (last 19.8%) and July Exports +19.5% year-over-year (last 13.6%)
  • In news:
  • Regional economic data included below-consensus Manufacturing PMI readings from India and Japan while China's Caixin Manufacturing PMI beat expectations.
  • The People's Bank of China reportedly uncovered operational violations at 40 Chinese banks. The banks maintain up to six months to correct the issues.
  • In Japan, Chief Cabinet Secretary Yoshihide Suga confirmed that Prime Minister Shinzo Abe plans to reshuffle his cabinet on August 3.
  • The Reserve Bank of Australia left its cash rate unchanged at 1.50%, as expected. The central bank notable that the relative energy of the Australian dollar results from weakness in the U.S. dollar.
  • The Reserve Bank of India will meet overnight.
  • Major European indices trade higher across the board while the euro (1.1814) has shed 0.2% against the dollar after hitting a 19-month high against the greenback yesterday afternoon. Germany's DAX +0.3%, France's CAC +0.5%, UK's FTSE +0.5%.
  • In economic data:
  • Eurozone Q2 GDP +0.6% quarter-over-quarter, as expected (last 0.5%); +2.1% year-over-year (consensus 2.4%; terminal 1.9%). July Manufacturing PMI 56.6 (expected 56.8; terminal 56.8)
  • Germany's July Manufacturing PMI 58.1 (expected 58.3; terminal 58.3). July Unemployment Change -9,000 (consensus -5,000; terminal 6,000) and Unemployment Rate held at 5.7%, as expected
  • UK's July Manufacturing PMI 55.1 (expected 54.4; terminal 54.2). July Nationwide HPI +0.3% month-over-month (expected -0.1%; terminal 1.1%); +2.9% year-over-year (consensus 2.7%; terminal 3.1%)
  • France's July Manufacturing PMI 54.9 (expected 55.4; terminal 55.4)
  • Italy's July Manufacturing PMI 55.1 (consensus 55.2; terminal 55.2)
  • Spain's July Manufacturing PMI 54.0 (expected 54.5; terminal 54.7)
  • In news:
  • British Chancellor Philip Hammond said Brexit will not exist postponed or delayed, but the balancing of the UK's budget may exist delayed.
  • 7:50 am Libbey misses by $0.21, reports revs in-line; reaffirms FY17 Outlook (LBY) :

  • Reports Q2 (Jun) loss of $0.04 per share, $0.21 worse than the Capital IQ Consensus of $0.17; revenues fell 5.0% year/year to $197.5 mln vs the $198.29 mln two analyst estimate.
  • Net sales in the U.S. and Canada segment were lower due to softer sales in the retail and business-to-business channels, which were down approximately 10 percent and 2 percent, respectively. U.S. and Canada foodservice net sales were flat versus prior year, despite volume increases in the channel.
  • In Latin America, net sales declined as a result of lower net sales across sum channels, primarily due to lower volume in the retail channel. Decreased volume in the business-to-business channel was offset by favorable charge and mix.
  • Net sales in the EMEA segment decreased primarily as a result of unfavorable currency.
  • Net sales in Other were down as a result of softer sales in China.
  • FY17 Outlook
  • Affirmed its previous full-year 2017 outlook, but indicated that it expects Adjusted EBITDA margin to exist near the low discontinue of its previously provided 11 percent to 13 percent range. 
  • Net sales decline in the low-to-mid solitary digits, compared to the complete year 2016, on a reported basis, with continued currency headwinds    
  • Capital expenditures of approximately $50 million.
  • "Second quarter sales results were in line with their expectations, as an intensely competitive pricing environment continues to linger on a global basis," said Chairman and Chief Executive Officer William Foley. "We remain confident that they are taking the commandeer measures to better the long-term performance of their business. We're seeing indications that inevitable pricing initiatives they implemented terminal quarter are taking hold, and that their novel product initiatives are rise to gain traction in the marketplace. We're furthermore very pleased that their novel e-commerce platform launched on time and on budget in mid-July."
  • 7:46 am On The Wires (:WIRES) :

  • Mateon Therapeutics (MATN) has completed enrollment of more than 80 patients in the side 2 portion of its FOCUS study evaluating CA4P in combination with bevacizumab (Avastin) and physician's selection chemotherapy for the treatment of platinum-resistant ovarian cancer.
  • Madrigal Pharmaceuticals (MDGL) has completed patient enrollment of 125 patients, exceeding its targeted enrollment of 117 patients, in its side 2 proof-of-concept study evaluating MGL-3196 for the treatment of non-alcoholic steatohepatitis (NASH). MGL-3196 is a first-in-class, oral, once-daily, liver-directed, thyroid hormone receptor (THR) -selective agonist medication. The primary endpoint is the reduction of liver fat, assessed by MRI-PDFF, at 12 weeks. The co expects to report top-line results by year-end.
  • Mallinckrodt Pharmaceuticals (MNK) confirmed inclusion of the first patient in the company's side 4 registry assessing the expend of INOMAX (nitric oxide) gas for inhalation for premature (less than 34 weeks gestational age) neonates versus term and near-term neonates (greater than 34 weeks gestational age).
  • 7:46 am Jacobs signed a global Enterprise Framework Agreement renewal with Shell Oil Company to provide concept, front-end engineering, circumstantial design, procurement, project management, construction management and construction services for Shell projects globally (JEC) :  

    7:40 am Intellia Therapeutics misses by $0.03, beats on revs (NTLA) :

  • Reports Q2 (Jun) loss of $0.45 per share, $0.03 worse than the Capital IQ Consensus of ($0.42); revenues rose 40.5% year/year to $5.9 mln vs the $5.83 mln Capital IQ Consensus. 
  • "We are very excited that their initial non-human primate data in vivo continue to validate their mRNA delivery technology. These preclinical data accelerate their momentum as they promote the evolution of potential therapies to treat patients with high unmet medical needs."
  • Primary uses of capital will continue to exist research and evolution programs, laboratory and related supplies, compensation and related expenses, legal and other regulatory expenses, patent prosecution, filing and maintenance costs for their licensed intellectual property, and generic overhead costs. During 2017, the company expects expenses to continue to extend compared to prior periods relating to their ongoing activities, particularly as research and evolution and preclinical activities assemble further momentum toward human clinical trials, and they disburse a complete year occupying their novel office and laboratory facility, which they began to occupy in the fourth quarter of 2016. await that the cash and cash equivalents as of June 30, 2017, as well as technology access and research funding from Novartis and Regeneron, will enable Intellia to fund operating expenses and capital expenditures through mid-2019, excluding any potential milestone payments or extension fees received under their collaboration agreements with Novartis and Regeneron.
  • 7:37 am Erin Energy announces the arrival of the Pacific Bora drilling rig to the Oyo realm offshore Nigeria, expected to double its production (ERN) :

    Erin Energy plans to expend Pacific Bora to drill the Oyo-9 well (Oyo-9) on the Oyo realm in deepwater offshore Nigeria.

  • The Company expects to commence drilling of Oyo-9 in ~10 days and the well to add an additional 6,000 to 7,000 barrels per day.
  • 7:37 am Zynerba Pharma misses by $0.05; Top-line side 2 results for STAR 1 affliction in epilepsy and discontinue affliction in osteoarthritis remain on track for reporting in August 2017 (ZYNE) :

  • Reports Q2 (Jun) loss of $0.64 per share, $0.05 worse than the Capital IQ Consensus of ($0.59). 
  • "We await to publish top-line results from the STAR 1 affliction soon, followed by top-line data from the discontinue affliction later this month; and they remain on track to report top-line results from the FAB-C brittle X study in September," said Armando Anido, Chairman and Chief Executive Officer. "We furthermore met a significant milestone during the quarter in initiating the side 1 program for ZYN001, a pro-drug of THC delivered via patch, and await to initiate their side 2 program by the discontinue of this year. With two clinical stage assets, Zynerba is well-positioned to address a number of sober unmet medical needs."
  • The Company believes that the current cash and cash equivalent position of $70.2 million is sufficient to develop five side 3-ready programs and, assuming uphold from the FDA to scurry forward, initiate at least one side 3 program and fund operations and capital requirements into 2019.
  • 7:36 am Affimed Therapeutics beats by $0.02, misses on revs (AFMD) :

  • Reports Q2 (Jun) loss of 0.18 per share, 0.02 better than the Capital IQ Consensus of (0.20); revenues fell 75.4% year/year to 0.51 mln vs the 1.31 mln Capital IQ Consensus.
  • "We are encouraged by the progress of their clinical programs, in particular moving into the expansion side of their AFM13 combination affliction with Keytruda," said Dr. Adi Hoess, CEO of Affimed. "In their preclinical programs addressing the medical exigency in solid tumors and multiple myeloma, they maintain designed and characterized well-differentiated molecules and determined advantages in safety and potency."
  • 7:35 am Cummins misses by $0.03, beats on revs; guides FY17 revs above consensus (CMI) :

  • Reports Q2 (Jun) earnings of $2.53 per share, $0.03 worse than the Capital IQ Consensus of $2.56; revenues rose 12.1% year/year to $5.08 bln vs the $4.8 bln Capital IQ Consensus.
  • Co issues upside guidance for FY17, sees FY17 revs of +9-11% (Approx $19.08-19.43 bln) vs. $18.52 bln Capital IQ Consensus Estimate.
  • Cummins expects complete year 2017 revenues to exist up 9 to 11 percent, higher than the prior forecast of up 4 to 7 percent.
  • EBIT is expected to exist in the gain of 11.75 to 12.5 percent of sales, unchanged from prior guidance. This forecast excludes the repercussion of their novel Eaton Cummins Automated Transmission Technologies joint venture.
  • 7:33 am Myers Industries beats by $0.04, reports revs in-line; reaffirms FY17 revs outlook (MYE) :

  • Reports Q2 (Jun) earnings of $0.17 per share, excluding non-recurring items, $0.04 better than the Capital IQ Consensus of $0.13; revenues fell 1.2% year/year to $142.3 mln vs the $142.95 mln Capital IQ Consensus.
  • The Company continues to anticipate that total revenue will exist flat on a constant currency basis in fiscal year 2017 as compared to the prior year.
  • 7:33 am TG Therapeutics and FDA gain agreement regarding a Special Protocol Assessment on the design of two side 3 clinical trials for TG-1101 for the treatment of relapsing forms of Multiple Sclerosis (TGTX) :

    The SPA provides agreement that the two side 3 affliction designs adequately address objectives that, if met, would uphold the regulatory submission for approval of TG-1101.

  • Co states, "The early data from their side 2 clinical trial, the highly successful pivotal results for the anti-CD20 monoclonal antibody ocrelizumab in MS, and the substantial safety data generated in their oncology program, gives us a high flush of confidence in the potential for a successful outcome. Their team in concert with their CRO has been arduous at drudgery on the logistics and the launch of these side 3 trials on a global basis, and they peer forward to enrolling their first patient before the discontinue of the summer."
  • 7:33 am Sprint beats by $0.10, reports revs in-line; raises profit guidance (S) :

  • Reports Q1 (Jun) earnings of $0.05 per share, $0.10 better than the Capital IQ Consensus of ($0.05); revenues rose 1.8% year/year to $8.16 bln vs the $8.14 bln Capital IQ Consensus, its fourth consecutive quarter of year-over-year growth, and 88,000 postpaid phone net additions, its eighth consecutive quarter of net additions. Postpaid phone indecorous additions furthermore grew year-over-year for the sixth consecutive quarter and were the highest first-quarter result in five years. "Sprint reached an Important milestone this quarter by returning to profitability for the first time in three years," said Sprint CEO Marcelo Claure. "This represents the progress of a turnaround journey that has delivered improvements in postpaid phone and prepaid customer growth, a return to top-line growth, and a significantly transformed cost structure."
  • Sprint continued to compose progress on its multiyear draw to transform the route it does business and better its cost structure. The company delivered nearly $370 million of combined year-over-year reductions in cost of services and SG&A expenses in the quarter, bringing the total reduction during the terminal nine quarters to nearly $4 billion. The ongoing cost-reduction program contributed to a return to profitability this quarter, as the company reported net income for the first time in three years. Excluding the after-tax benefit of non-recurring items in the quarter, Sprint would maintain reported net income of more than $150 million, demonstrating the improved underlying trends of the business. Sprint expects an additional $1.3 billion to $1.5 billion of year-over-year net reductions in cost of services and SG&A expenses in fiscal year 2017. Although the indecorous reductions are expected to exist higher, the company plans to reinvest some of the savings into future growth initiatives.
  • The company is increasing the low discontinue of its previous Adjusted EBITDA* expectations and now expects $10.8 billion to $11.2 billion for fiscal year 2017. The previous expectation was $10.7 billion to $11.2 billion. The company is increasing the low discontinue of its previous operating income expectations and now expects operating income of $2.1 billion to $2.5 billion. The previous expectation was $2 billion to $2.5 billion. The company continues to await cash capital expenditures, excluding devices leased through roundabout channels, of $3.5 billion to $4 billion.
  • 7:33 am CDK Global beats by $0.01, beats on revs; guides FY18 EPS above consensus (CDK) :

  • Reports Q4 (Jun) earnings of $0.55 per share, excluding non-recurring items, $0.01 better than the Capital IQ Consensus of $0.54; revenues rose 4.3% year/year to $565.4 mln vs the $556.68 mln Capital IQ Consensus.
  • Co issues upside guidance for FY18, sees EPS of $2.90-3.00, excluding non-recurring items, vs. $2.93 Capital IQ Consensus Estimate.
  • "I am pleased with the results of their fiscal year and benefits delivered by executing their transformation plan. Adjusted EBITDA margin expansion of 550 basis points in fiscal 2017, combined with the 370 basis points of expansion achieved in fiscal 2016, puts us on track to achieve their transformation goals," said Brian MacDonald, chief executive officer. "By improving their products and processes and focusing on their dealer customers, they are making solid progress. Based on successes to date, they await to exceed the fiscal 2018 adjusted EBITDA target of 35%."
  • 7:32 am Eyegate Pharmaceuticals has enrolled its first patient in the Company's side 2b clinical affliction of its EGP-437 combination product (EYEG) :

    The EyeGate II Delivery System and EGP-437 combination product, is being evaluated for the treatment of smart and inflammation in patients having undergone cataract surgery with implantation of a monofocal posterior chamber IOL.  

  • As announced in the first quarter of 2017, EyeGate and Valeant (VRX) entered into an exclusive, worldwide licensing agreement through which EyeGate has granted a subsidiary of Valeant exclusive, worldwide commercial and manufacturing rights to the EGP-437 combination product candidate for the treatment of post-operative ocular inflammation and smart in ocular surgery patients.
  • 7:31 am Flex Pharma initiates side 2 CONMEND affliction in the US, will evaluate FLX-787 in patients with motor neuron disease, focused on ALS, who suffer from painful, debilitating cramps; co expects to report topline results from this study in the middle of 2018 (FLKS) :

    The co has initiated a side 2 randomized, controlled, double-blinded, parallel design affliction in the US, referred to as the COMMEND trial.

  • The COMMEND affliction will evaluate FLX-787, the Company's co-activator of TRPA1 and TRPV1, in patients with motor neuron disease, focused on ALS, who suffer from painful, debilitating cramps.
  • The FDA has granted FLX-787 hasty Track designation for the treatment of strict muscle cramps associated with ALS.
  • The Company expects to report topline results from this study in the middle of 2018.
  • The Company furthermore intends to initiate a side 2 clinical affliction in CMT this quarter.
  • 7:29 am Penske Auto commences $300 mln offering of Senior Subordinated Notes due 2020 (PAG) : The company intends to expend the net proceeds of this offering to repay amounts currently outstanding under the company's U.S. credit agreement and for generic working capital purposes.

    7:25 am Martin Marietta misses by $0.10, misses on revs; guides FY17 revs in-line (MLM) :

  • Reports Q2 (Jun) earnings of $2.25 per share, $0.10 worse than the Capital IQ Consensus of $2.35; revenues rose 8.8% year/year to $996.3 mln vs the $1014.78 mln Capital IQ Consensus.
  • Building Materials net sales of $931.7 million compared with $856.6 million, an extend of 8.8%, and Magnesia Specialties net sales of $64.6 million compared with $58.8 million, an extend of 9.7%
  • Consolidated indecorous profit of $274.1 million compared with $247.4 million, an extend of 10.8%
  • Co issues in-line guidance for FY17, sees FY17 revs of $3.75-3.95 bln vs. $3.93 bln Capital IQ Consensus Estimate.
  • Infrastructure market to extend mid-single digits.
  • Nonresidential market to extend in the low- to mid-single digits.
  • Residential market to extend in the mid- to high-single digits.
  • ChemRock/Rail market to remain stable.
  • 2017 consolidated net sales exclude $390 million related to estimated interproduct sales.
  • Ward Nye, Chairman, President and CEO of Martin Marietta, stated, "Our record second-quarter results reflect improved sales, indecorous profit and earnings from operations in each reportable group, underscoring the breadth of their business and their talent to capitalize on the ongoing recovery in construction activity. Positive residential and nonresidential activity drove results, along with pricing improvements across their aggregates product line, led by the Southeast Group's 10.6 percent increase. They overcame challenging operating conditions in several key states, as near-record levels of precipitation in North Carolina, South Carolina, Georgia and Florida negatively impacted aggregates shipments and operating efficiencies in their historically most profitable geographic areas. Looking ahead, they are optimistic about the balance of 2017 and beyond due to increased momentum across almost their entire geographic footprint and the positive near- and medium-term outlooks expressed by their customers."
  • 7:20 am Intesa Sanpaolo reports H1 results (ISNPY) :

  • Net income was 1,738 million excluding the aforementioned public contribution and 2,198 million excluding, in addition, levies and other charges concerning the banking industry.
  • Net interest income in Q2 2017 up 0.6% on Q1 2017, and in H1 2017 up 1.5% on H1 2016 when excluding the repercussion of the devaluation of the Egyptian currency.
  • The credit character trend improved. the past 21 months recorded a 10 billion indecorous npl stock reduction, which was achieved at no extraordinary cost to shareholders. in q2 2017, indecorous npl inflow from performing loans was at its lowest since the creation of intesa sanpaolo.
  • 7:18 am Lifepoint Hospitals beats by $0.06, misses on revs; guides FY17 EPS lower, revs below consensus (LPNT) :

  • Reports Q2 (Jun) earnings of $0.96 per share, excluding non-recurring items, $0.06 better than the Capital IQ Consensus of $0.90; revenues rose 0.2% year/year to $1.59 bln vs the $1.64 bln Capital IQ Consensus.
  • William F. Carpenter III, Chairman and Chief Executive Officer of LifePoint Health, said, "We are pleased to deliver another quarter of solid results with EBITDA growth and expanded margins both year-over-year and sequentially. Their longstanding operating discipline continues to exist integral to their success even while the volume environment remains challenging. They are successfully integrating recently acquired hospitals and health systems and remain committed to their strategic priorities of character and service, growth, operational excellence and talent evolution at every location to drive long-term value for their shareholders."
  • Co issues guidance for FY17, sees EPS of $3.92-$4.20 vs. $4.19 Capital IQ Consensus assess and prior guidance of $4.05-$4.34; sees FY17 revs of $6.425-$6.500 bln vs. $6.55 bln Capital IQ Consensus assess and prior guidance of $6.50-$6.60 bln.
  • 7:18 am European Markets Update: DAX +0.3%, CAC +0.5%, FTSE +0.5% (:SUMRX) :

    Major European indices trade higher across the board while the euro (1.1814) has shed 0.2% against the dollar after hitting a 19-month high against the greenback yesterday afternoon. British Chancellor Philip Hammond said Brexit will not exist postponed or delayed, but the balancing of the UK's budget may exist delayed.

  • In economic data:
  • Eurozone Q2 GDP +0.6% quarter-over-quarter, as expected (last 0.5%); +2.1% year-over-year (consensus 2.4%; terminal 1.9%). July Manufacturing PMI 56.6 (expected 56.8; terminal 56.8)
  • Germany's July Manufacturing PMI 58.1 (expected 58.3; terminal 58.3). July Unemployment Change -9,000 (consensus -5,000; terminal 6,000) and Unemployment Rate held at 5.7%, as expected
  • UK's July Manufacturing PMI 55.1 (expected 54.4; terminal 54.2). July Nationwide HPI +0.3% month-over-month (expected -0.1%; terminal 1.1%); +2.9% year-over-year (consensus 2.7%; terminal 3.1%)
  • France's July Manufacturing PMI 54.9 (expected 55.4; terminal 55.4)
  • Italy's July Manufacturing PMI 55.1 (consensus 55.2; terminal 55.2)
  • Spain's July Manufacturing PMI 54.0 (expected 54.5; terminal 54.7)
  • ---Equity Markets---

  • Germany's DAX is higher by 0.3% with most components trading in the green. Lufthansa has spiked 2.6% while Prosiebensat 1, Heidelbergcement, and Infineon are up between 1.0% and 1.2%. BMW, Daimler, and Volkswagen demonstrate gains between 0.6% and 1.0%. Adidas is the weakest component, falling 0.7%.
  • France's CAC trades up 0.5% with heavyweights among the leaders. Peugeot, Airbus Group, Renault, Louis Vuitton, and Total maintain added between 1.1% and 1.5%. A handful of consumer names lag with L'Oreal, Danone, and Pernod Ricard shedding between 0.2% and 1.1%.
  • UK's FTSE has climbed 0.5%. Rolls-Royce has surged 9.4% in reaction to upbeat earnings while BP has climbed 2.7% after it too beat estimates. Consumer stocks dote Paddy Power, Imperial Brands, Taylor Wimpey, Burberry, and British American Tobacco demonstrate gains between 0.9% and 1.7%. On the downside, select miners dote Fresnillo, Anglo American, and Randgold Resources demonstrate losses between 0.6% and 2.5%.
  • 7:17 am Broadwind Energy reports EPS in-line, revs in-line; guides Q3 EPS below two analyst estimate, revs below consensus (BWEN) :

  • Reports Q2 (Jun) loss of $0.05 per share, in-line with the Capital IQ Consensus of ($0.05); revenues were unchanged from the year-ago epoch at $43.4 mln.
  • Co issues downside guidance for Q3, sees EPS of ($0.15)-(0.17), excluding non-recurring items, vs. $0.02 two analyst estimate; sees Q3 revs of $30 mln vs. $41.25 mln Capital IQ Consensus Estimate.
  • Q4 outlook highly uncertain due to change in tower procurement and engineering practices.
  • 7:16 am ACCO Brands beats by $0.05, misses on revs; raises FY17 EPS guidance to exist at the high discontinue of prior range, in-line, reaffirms revs in-line (ACCO) :

  • Reports Q2 (Jun) earnings of $0.31 per share, excluding non-recurring items, $0.05 better than the Capital IQ Consensus of $0.26; revenues rose 19.5% year/year to $490 mln vs the $497.17 mln Capital IQ Consensus.
  • Co raises 2017 EPS guidance....
  • Co expects FY17 EPS to exist at the high discontinue of its prior adjusted EPS range, at $1.07-1.10, excluding non-recurring items, vs. $1.08 Capital IQ Consensus Estimate; reaffirms FY17 revenue growth expectation of 22-26%, which equates to roughly $1.90-1.96 vs. $1.94 bln Capital IQ Consensus Estimate.
  • 7:15 am Endurance International misses by $0.11, reports revs in-line; updates guidance (EIGI) :

  • Reports Q2 (Jun) GAAP loss of $0.29 per share, $0.11 worse than the Capital IQ GAAP consensus assess of ($0.18); revenues rose 0.5% year/year to $292.26 mln vs the $289.4 mln Capital IQ Consensus.
  • Total subscribers on platform at June 30, 2017 were approximately 5.217 million, compared to approximately 5.480 million subscribers at June 30, 2016 and 5.304 million subscribers at March 31, 2017.
  • Adjusted EBITDA for the second quarter of 2017 was $82.5 million, an extend of 7 percent compared to $76.9 million for the second quarter of 2016.
  • Updated Guidance:
  • Co sees GAAP revenue +5-5.5% (Prior 4-5%)
  • Co sees Adjusted EBITDA +14-16% (Prior +12-14%)
  • Co sees Free cash flux +25% (Prior +35%)
  • 7:15 am Scotts Miracle-Gro beats by $0.12, beats on revs; reaffirms FY17 guidance; expects to rasie dividend in near future (SMG) :

  • Reports Q3 (Jun) earnings of $2.63 per share, $0.12 better than the Capital IQ Consensus of $2.51; revenues rose 8.5% year/year to $1.08 bln vs the $1.06 bln Capital IQ Consensus. U.S. Consumer increased 5 percent to $792.2 million from $756.7 million. Europe Consumer sales declined 3 percent, but increased 2 percent when excluding the repercussion of alien exchange rates, to $93.2 million. Sales in the "Other" segment increased 36 percent to $192.6 million due to the acquisitions of Botanicare and Gavita as well as year-over- year growth within The Hawthorne Gardening Company.
  • Co reaffirms guidance for FY17, sees EPS of $4.00-4.20, excluding non-recurring items, vs. $4.13 Capital IQ Consensus Estimate; sees FY17 revs of +3-4% to $2.92-2.95 bln vs. $2.93 bln Capital IQ Consensus Estimate. 
  • The Company now expects to complete the pending sale of its European and Australian businesses in the fourth quarter and anticipates lowering its guidance for Non-GAAP adjusted earnings by ~$0.20 per share at that time. "Once this pending divestiture is behind us, the material changes in reconfiguration of their portfolio will largely exist behind us," Hagedorn said. "Where appropriate, they will continue to seek tuck-in acquisitions that complement their remaining portfolio, however, their color going forward will exist to return cash to shareholders. They await to extend their quarterly dividend in the near future and will continue to exist an energetic acquirer of their shares." 
  • 7:15 am Lexicon Pharma beats by $0.11, misses on revs (LXRX) :

  • Reports Q2 (Jun) loss of $0.33 per share, $0.11 better than the Capital IQ Consensus of ($0.44); revenues fell 40.3% year/year to $12 mln vs the $18.34 mln Capital IQ Consensus.
  • Anticipated Upcoming Milestones September 11-15, 2017 -- Two oral presentations (inTandem2 and JDRF studies) and two poster presentations (dose ranging and in Tandem studies) at the 53rd Annual Meeting of the European Association for the Study of Diabetes (:EASD) in Lisbon. Q3 2017 - Secondary endpoint data from inTandem. Q3 2017 - Pooled continuous glucose monitoring (:CGM) data from inTandem1 and inTandem.
  • 7:13 am On The Wires (:WIRES) :

  • Magellan Health (MGLN) has launched a hemophilia management program in collaboration with Health novel England, a non-profit health draw serving the commercial, Medicaid and Medicare markets.
  • Spectrum Pharmaceuticals (SPPI) has completed enrollment with 405 patients randomized in the ROLONTIS side 3 promote pivotal study under a Special Protocol Assessment (SPA) with the FDA. The study is evaluating the safety and efficacy of ROLONTIS in the management of chemotherapy-induced neutropenia in patients with breast cancer. Enrollment has been completed ahead of schedule. The Company plans to publish topline data in Q1 2018 and file a Biologics License Application (:BLA) next year.
  • Acceleron Pharm (XLRN) announced that the first patient has been treated in a side 2 clinical affliction of ACE-083, the Company's locally acting muscle agent, for the treatment of patients with Charcot-Marie-Tooth disease (CMT).
  • 7:12 am Government Properties Income faith beats by $0.01, beats on revs (GOV) :

  • Reports Q2 (Jun) funds from operations of $0.60 per share, $0.01 better than the Capital IQ Consensus of $0.59; revenues rose 9.1% year/year to $69.89 mln vs the $69.08 mln Capital IQ Consensus.
  • Completed 288,428 Square Feet of Leasing in the Second Quarter for a 13.5% extend in Rents.
  • Occupancy was 95.0% at Quarter End, Up 80 Basis Points Year Over Year.
  • Announced Agreement to Acquire First Potomac Realty faith for Approximately $1.4 Billion.
  • "Government Properties Income faith achieved solid leasing results during the second quarter of 2017. They entered into novel and renewal leases for over 288,000 square feet of space for rents that were 13.5% higher than previous rents for the identical space. They furthermore announced their planned strategic acquisition of First Potomac Realty faith and began to implement their long term financing and business repositioning plans associated with that acquisition by raising $494 million of net proceeds from the sale of common equity and the issuance of $300 million aggregate principal amount of senior unsecured notes due 2022."
  • 7:11 am Oxford Immunotec misses by $0.42, beats on revs; guides Q3 revs in-line; raises FY17 revs guidance in-line (OXFD) :

  • Reports Q2 (Jun) loss of $0.74 per share, $0.42 worse than the two analyst assess of ($0.32); revenues rose 35.9% year/year to $26.1 mln vs the $25.05 mln Capital IQ Consensus.
  • Co issues in-line guidance for Q3, sees Q3 revs of $29.5-$30.5 mln vs. $30.38 mln Capital IQ Consensus Estimate.
  • Co issues in-line guidance for FY17, sees FY17 revs of $103.0-$106.0 mln vs. $103.99 mln Capital IQ Consensus assess and prior guidance of $102.0-$105.0 mln.
  • 7:11 am IDEXX Labs beats by $0.02, beats on revs; raises FY17 guidance (IDXX) :

  • Reports Q2 (Jun) earnings of $0.87 per share, excluding non-recurring items, $0.02 better than the Capital IQ Consensus of $0.85; revenues rose 9.1% year/year to $508.9 mln vs the $502.44 mln Capital IQ Consensus.
  • Co issues raised guidance for FY17, sees EPS of $3.12-3.22 from $2.95-3.11 vs. $3.07 Capital IQ Consensus Estimate; raises FY17 revs to $1.945-1.965 bln from $1.925-1.95 bln vs. $1.94 bln Capital IQ Consensus Estimate.
  • Gross profits increased 12%, and indecorous margin increased to 57.5% from 55.8% in the prior year period.
  • 7:11 am Phillips 66 Partners misses by $0.07, reports revs in-line (PSXP) :

  • Reports Q2 (Jun) earnings of $0.61 per share, $0.07 worse than the Capital IQ Consensus of $0.68; revenues were unchanged from the year-ago epoch at $234 mln.
  • Adjusted EBITDA was $170 million in the second quarter, compared with $155 million in the prior quarter.
  • The Sand Hills Pipeline expansion continues to progress. The project will expand capacity from 280,000 barrels per day (:BPD) to 365,000 BPD, with an expected in-service date by the discontinue of 2017. In addition, DCP Midstream, the operator of the pipeline, has announced plans to further expand the line to approximately 450,000 BPD. Phillips 66 Partners owns a one-third interest in this joint venture.
  • 7:11 am Colliers beats by $0.08, beats on revs (CIGI) :

  • Reports Q2 (Jun) earnings of $0.76 per share, excluding non-recurring items, $0.08 better than the Capital IQ Consensus of $0.68; revenues rose 12.8% year/year to $544.2 mln vs the $515.45 mln Capital IQ Consensus.
  • 7:10 am Incyte misses by $0.02, beats on revs; raises sales guidance (INCY) :

  • Reports Q2 (Jun) loss of $0.06 per share, $0.02 worse than the Capital IQ Consensus of ($0.04); revenues rose 32.5% year/year to $326.4 mln vs the $318.45 mln Capital IQ Consensus. Net product revenues of Jakafi were $276 million as compared to $208 million for the identical epoch in 2016, representing 33 percent growth.
  • Raises Jakafi net rev to $1.09-1.12 bln from $1.02-1.07 bln; reaffirms Iclusig $60-65 mln. Proof-of-concept data for the combination of epacadostat plus PD-1 inhibition presented at the American Society of Clinical Oncology Annual Meeting (:ASCO) 2017 across multiple tumor types; expanded side 3 program on track for planned initiation in 2017 Multiple product candidates in late-stage clinical evolution illustrates transformational growth potential of Incyte's portfolio.
  • "Revenue growth from Jakafi and Iclusig continues to exist very robust, driven by stalwart demand, and they maintain furthermore made significant progress across their clinical portfolio. As they peer forward to the second half of 2017, they anticipate the publication of Important data from their evolution candidates, as well as the initiation of multiple additional pivotal combination studies with epacadostat."
  • 7:10 am Innophos Holdings beats by $0.04, beats on revs; guides Q3 revs below two analyst estimate; reaffirms FY17 EPS guidance, revs guidance (IPHS) :

  • Reports Q2 (Jun) earnings of $0.57 per share, excluding non-recurring items, $0.04 better than the two analyst assess of $0.53; revenues fell 1.5% year/year to $179.14 mln vs the $172.65 mln two analyst estimate.
  • All segments showed positive year-over-year volume comparisons
  • Delivered final $2 million of $16 million procurement savings pipeline from side 1 Operational Excellence initiatives
  • H2 2017 on track to realize $5 million of the identified $13 million side 2 Operational Excellence cost savings in the areas of MRO, packaging and logistics
  • The acquisition of Novel Ingredients will create a Food, Health and Nutrition (FHN) platform of nearly $0.5 billion in revenue representing 60% of total sales. The combined Company will benefit from leading, innovative technology; a broader and deeper product portfolio; and access to novel market segments
  • Co issues downside guidance for Q3, sees Q3 revs of down ~4% y/y to ~$178.59 mln vs. $186.30 mln two analyst estimate.
  • Earnings in the third quarter are forecast to exist positively affected sequentially by reduced implementation fees and first-time cost savings from side 2 operational excellence.
  • Input costs are otherwise expected to exist in line with second quarter 2017.
  • The Company anticipates that the tax rate will exist at the more normalized flush of approximately 33% in the thirdquarter.
  • Co reaffirms guidance for FY17, sees EPS of broadly in line with 2016 which was $2.55 vs. $2.48 two analyst estimate; sees FY17 revs of ~$696 mln vs. $692.45 mln Capital IQ Consensus Estimate.
  • On a full-year basis, overall market conditions and the competitive landscape for 2017 are expected to exist similar to 2016.
  • The Company anticipates that the side 2 Operational Excellence fees incurred in the first half of the year will exist more than offset by the side 2 savings, of which $5 million is estimated to engage result in the second half of 2017.
  • As a result of these factors, the Company continues to await full-year revenues to exist down by approximately 4% compared with 2016 (equates to ~$696 mln). The Company further continues to await full-year earnings to exist broadly in line with 2016, reflecting the repercussion of management's focus on cost actions and productivity initiatives given the challenging market conditions.
  • "We delivered a very robust second quarter with top and bottom line results above their expectations," said Kim Ann Mink, Ph.D., Chairman, President and Chief Executive Officer. "By remaining focused on cost savings from performance improvement initiatives, they grew margins on a year-over-year basis despite continuing market pressure. As they transition into the second half of the year, they are encouraged by several recent developments, including improvements in sales volume. They are confident in their talent to deliver on a stalwart second half of the year and are reiterating their guidance, excluding the Novel Ingredients acquisition.
  • 7:09 am Schneider National reports EPS in-line, revs in-line; raises low-end of FY17 EPS guidance (SNDR) :

  • Reports Q2 (Jun) earnings of $0.23 per share, excluding non-recurring items, in-line with the Capital IQ Consensus of $0.23; revenues rose 8.1% year/year to $1.08 bln vs the $1.07 bln Capital IQ Consensus.
  • Co raises guidance for FY17, sees EPS of $0.94-1.02 (Prior $0.92-1.02) , excluding non-recurring items, vs. $0.97 Capital IQ Consensus Estimate.
  • "The market pressures of the first quarter continued into the second quarter," said Lofgren. "However, in June indications of improving market conditions began to appear. July is always a challenging month, so they will maintain a better read by mid-August, but they are cautiously optimistic that the market will behold strengthening in the second half of 2017. The market improvement, their efforts to extend driver capacity, novel Dedicated contracts and their ongoing revenue management drudgery positions us well for the second half of 2017. terminal quarter, I discussed my commitment to exist thoughtful and disciplined as to capital expenditures. In light of anticipated market improvement and novel customer wins, they maintain increased their anticipated complete year net capital expenditures gain to $350 million to $400 million which includes $100 million for chassis. Further, they anticipate complete year 2017 adjusted diluted earnings per share in the gain of $0.94 to $1.02, which includes the repercussion of increased share signify from the IPO estimated at $0.10 per share."
  • 7:08 am Phillips 66 beats by $0.08 (PSX) :

  • Reports Q2 (Jun) earnings of $1.09 per share, $0.08 better than the Capital IQ Consensus of $1.01.
  • Phillips 66 generated $1.9 billion in cash from operations during the second quarter, including $422 million of cash distributions from equity affiliates. Excluding working capital impacts, operating cash flux was $1.2 billion.
  • During the quarter, Phillips 66 funded $458 million of capital expenditures and investments, and distributed $360 million in dividends and $381 million in share repurchases. The company ended the quarter with 512 million shares outstanding.
  • As of June 30, 2017, cash and cash equivalents were $2.2 billion, and consolidated debt was $10.0 billion, including $2.3 billion at Phillips 66 Partners (PSXP). The company's consolidated debt-to-capital ratio and net-debt-to-capital ratio were 30 percent and 25 percent, respectively. Excluding PSXP, the debt-to-capital ratio was 26 percent and net-debt-to-capital ratio was 20 percent.
  • 7:07 am Dorman Products misses by $0.02, beats on revs (DORM) :

  • Reports Q2 (Jun) earnings of $0.83 per share, $0.02 worse than the Capital IQ Consensus of $0.85; revenues rose 9.4% year/year to $229.26 mln vs the $225.91 mln Capital IQ Consensus.
  • "In the quarter, they furthermore started to realize meaningful revenue from the launch of their Dorman Premium complete line chassis program. They are truly excited to behold the results of a lot of arduous drudgery by the team as they strive to become a market leader in this category. Overall, they continue to execute well, and although they are very pleased with their first half growth, they remain cautious entering the back half of the year given current market conditions. However, their previously issued complete year guidance for top and bottom line growth remains unchanged" said Matt Barton, President and Chief Executive Officer.
  • Operating Cash flux was $3.8 million in the quarter compared to $12.6 million in the identical quarter terminal year. Investment in inventories (of approximately $29 million in the quarter), to ensure high customer fill rates, was the driver of the decreased Operating Cash Flows. They await inventory to plateau in the third quarter and originate to decline slightly in the second half of the year.
  • 7:05 am Innophos Holdings to acquire Novel Ingredients for $125 mln in cash (IPHS) :

    Novel Ingredients are a novel Jersey-based provider of dietary supplement ingredient solutions primarily owned by GenNx360 Capital Partners, a novel York-based private equity firm.

  • Under the terms of the merger agreement, Innophos will acquire sum of the outstanding shares of Novel Ingredients for a total purchase charge of $125 million (enterprise value), payable in cash.
  • Co will fund the acquisition with borrowings under its existing credit facility.
  • The acquisition is expected to exist accretive to Innophos' earnings per share in the first year following the close of the transaction.
  • Closing of the transaction is expected to exist completed in the third quarter of 2017.
  • Annual revenue of nearly $100 million; 2008-2016 CAGR of 19%.
  • Annual cost synergies estimated at $4 million; revenue synergies are anticipated from combined product technology and customer relationships
  • 7:05 am Shopify beats by $0.06, beats on revs; guides Q3 revs above consensus; raises FY17 above consensus; CFO will retire (SHOP) :

  • Reports Q2 (Jun) adj. loss of $0.01 per share, $0.06 better than the Capital IQ Consensus of ($0.07); revenues rose 75.2% year/year to $151.7 mln vs the $143.94 mln Capital IQ Consensus. Within this, Subscription Solutions revenue grew 64% to $71.6 million. The acceleration in Subscription Solutions revenue growth was driven by the continued rapid growth in Monthly Recurring Revenue as another record number of merchants joined the platform in the period. Merchant Solutions revenue grew 86% to $80.1 million, driven primarily by the growth of indecorous Merchandise Volume.MRR as of June 30, 2017 was $23.7 million, up 64% compared with $14.4 million as of June 30, 2016. Shopify Plus contributed $4.3 million, or 18%, of MRR compared with 13% of MRR as of June 30, 2016.GMV for the second quarter was $5.8 billion, an extend of $2.5 billion, or 74% over the second quarter of 2016. indecorous Payments Volume3 ("GPV") grew to $2.2 billion, which accounted for 38% of GMV processed in the quarter, versus $1.3 billion, or 38%, for the second quarter of 2016.Gross profit dollars grew 83% to $86.8 million as compared with the $47.5 million recorded for the second quarter of 2016.
  • Co issues upside guidance for Q3, sees Q3 revs of $164-166 mln vs. $157.03 mln Capital IQ Consensus Estimate; adj. operating loss $2-4 mln
  • Co issues upside guidance for FY17, sees FY17 revs of $642-648 mln vs. $627.77 mln Capital IQ Consensus Estimate; adj. operating loss $7-11 mln
  • Shopify's Chief pecuniary Officer Russ Jones has informed the Company and its Board of Directors of his decision to retire in 2018. Russ, who joined Shopify in 2011, intends to continue to serve as CFO until his successor is create and has transitioned into the role, a process that is now underway and that Shopify expects will exist completed within the next 12 months.
  • 7:05 am Archer-Daniels beats by $0.05, misses on revs (ADM) :

  • Reports Q2 (Jun) earnings of $0.57 per share, excluding non-recurring items, $0.05 better than the Capital IQ Consensus of $0.52; revenues fell 4.4% year/year to $14.94 bln vs the $15.86 bln Capital IQ Consensus.
  • "Our actions in the first half of the year reflect ADM's continuous efforts to create shareholder value. They are diversifying their capabilities and geographic gain through acquisitions and organic expansions. They are aggressively managing costs and capital, and taking additional portfolio actions; and they are ahead of pace to meet their 2017 target of $225 million in run-rate savings...With these collective actions, they await to deliver solid year-over-year earnings growth and returns in 2017, and they are poised to exist an even stronger company in 2018."
  • 7:03 am CME Group beats by $0.01, reports revs in-line (CME) :

  • Reports Q2 (Jun) earnings of $1.22 per share, excluding non-recurring items, $0.01 better than the Capital IQ Consensus of $1.21; revenues rose 2.1% year/year to $925 mln vs the $931.05 mln Capital IQ Consensus.
  • Second-quarter 2017 impartial daily volume was a record 16.5 million contracts, up 9 percent compared with second-quarter 2016.
  • Clearing and transaction fee revenue was $792 million, up 3 percent compared with second-quarter 2016.
  • Second-quarter 2017 total impartial rate per condense was 74.9 cents, up 2 percent from first-quarter 2017, driven primarily by a sequential product coalesce shift with an increased balance of the volume from commodity contracts, which capture higher fees.
  • Market data revenue was $96 million, down 7 percent compared with the second quarter terminal year, but relatively in line with the first quarter of this year.
  • 7:03 am Steven Madden beats by $0.06, beats on revs; raises FY17 EPS, revs guidance (SHOO) :

  • Reports Q2 (Jun) earnings of $0.51 per share, excluding non-recurring items, $0.06 better than the Capital IQ Consensus of $0.45; revenues rose 15.0% year/year to $374.15 mln vs the $355.22 mln Capital IQ Consensus.
  • Gross margin was 37.3%. Adjusted indecorous margin was 37.4% as compared to 37.2% in the identical epoch terminal year, an extend of 20 basis points.
  • Same store sales increased 2.2% in the quarter compared to a 5.4% identical store sales extend in the second quarter of 2016. Retail indecorous margin decreased slightly to 62.6% in the second quarter of 2017 as compared to 62.8% in the second quarter of the prior year.
  • Co raises guidance for FY17, sees EPS of $2.18-2.24 (Prior $2.12-2.18), excluding non-recurring items, vs. $2.19 Capital IQ Consensus Estimate; sees FY17 revs of $1.53-1.55 bln (+9-11%) (Prior +8-10%) vs. $1.53 bln Capital IQ Consensus Estimate.
  • 7:03 am AcelRx reported key results from the side 3 IAP312 study of ZALVISO (sufentanil sublingual tablet system), an investigational product candidate being developed for the management of moderate-to-severe acute smart (ACRX) :

    Throughout the study in 320 enrolled patients, 2.2% of patients experienced a ZALVISO device error, which was statistically less than the 5% confine specified in the study objectives.

  • Importantly, not anyone of these device errors resulted in an over-dosing event.
  • This 2.2% rate was lower than the 7.9% rate of device errors during patient expend previously reported for the earlier version of the ZALVISO device in the side 3 IAP311 study.
  • In addition, as requested by FDA, the IAP312 study prospectively evaluated the number of inadvertently misplaced tablets which occurred during patient dosing.
  • No patient had a repeat incidence of an inadvertently misplaced tablet followingre-training on the device.
  • 7:03 am Pitney Bowes misses by $0.03, reports revs in-line; guides FY17 EPS in-line (PBI) :

  • Reports Q2 (Jun) earnings of $0.33 per share, excluding non-recurring items, $0.03 worse than the Capital IQ Consensus of $0.36; revenues fell 1.7% year/year to $821.4 mln vs the $822.9 mln Capital IQ Consensus.
  • Co issues narrows guidance for FY17, sees EPS of $1.70-1.78 from $1.70-1.85 vs. $1.74 Capital IQ Consensus Estimate.
  • Revenue, on a constant currency basis, to exist in the gain of flat to 1 percent growth, when compared to 2016. This has been updated from the original gain of a 2 percent decline to 1 percent growth. Free cash flux to exist in the gain of $400 million to $430 million. This has been updated from the original gain of $400 million to $460 million.
  • 7:03 am Caterpillar CFO Brad Halverson to retire in early 2018; co will launch an external search to fill the position (CAT) :  

    7:02 am Under Armour beats by $0.03, beats on revs; lowers FY17 guidance; announces restructuring (UAA) :

  • Reports Q2 (Jun) loss of $0.03 per share, excluding non-recurring items, $0.03 better than the Capital IQ Consensus of ($0.06); revenues rose 8.7% year/year to $1.09 bln vs the $1.08 bln Capital IQ Consensus, up 8 percent currency neutral. Revenue to wholesale customers rose 3 percent to $655 million and direct-to-consumer revenue was up 20 percent to $386 million. A dynamic and promotional retail environment in North America continued to temper results with revenue in line with terminal year's identical period. Outside North America, the stalwart momentum continued with international revenue up 57 percent (up 54 percent currency neutral), representing 22 percent of total revenue. Within their international business, revenue in EMEA was up 57 percent (up 53 percent currency neutral), up 89 percent in Asia-Pacific (up 87 percent currency neutral) and up 10 percent in Latin America (up 9 percent currency neutral). Apparel revenue increased 11 percent to $681 million including energy in men's and women's training, and golf. Footwear revenue was down 2 percent to $237 million, against terminal year's identical epoch which was up 58 percent due to significant energy in basketball sales. Accessories revenue increased 22 percent to $123 million with energy in men's and women's training, and youth performance.
  • Gross margin declined 190 basis points to 45.8 percent as benefits from channel and product coalesce were offset by inventory management initiatives, changes in alien currency rates, and higher air freight in connection with their enterprise resource planning (:ERP) system implementation, which impacted the timing of shipments to inevitable key customers.
  • Co issues guidance for FY17, sees EPS of $0.37-0.40, excluding non-recurring items, vs. $0.42 Capital IQ Consensus Estimate; sees FY17 revs of +9-11% to ~$5.26-5.36 bln vs. $5.35 bln Capital IQ Consensus Estimate. 
  • Under Armour's Board of Directors has approved a restructuring draw to more closely align its pecuniary resources to uphold the company's efforts to better serve the evolving needs of the changing consumer and customer landscape. "As they stand up their category management structure within a consumer-led approach, they intend to meaningfully extend their go-to-market quicken and amplify their digital capabilities," continued Plank. "We've identified a number of areas to enhance their operational capabilities, drive process improvement and gain greater efficiencies. They remain steadfast in driving and structure their brand while shifting their operational focus to become more return-on-investment and cost of capital centric - institutionalizing discipline to deliver more consistent, long-term shareholder value." In conjunction with this plan, the company expects to incur total estimated pre-tax restructuring and related charges of ~$110-130 million. 
  • 7:01 am Cara Therapeutics appoints Mani Mohindru, Ph.D., as CFO efficient August 15 (CARA) :

  • Josef Schoell, who has held the CFO position at Cara for more than a decade, will exist retiring.
  • Most recently, Mohindru served as Chief Strategy Officer at Curis (CRIS)
  • 7:01 am Granite Constr misses by $0.20, beats on revs (GVA) :

  • Reports Q2 (Jun) earnings of $0.35 per share, excluding non-recurring items, $0.20 worse than the Capital IQ Consensus of $0.55; revenues rose 26.2% year/year to $762.9 mln vs the $684.32 mln Capital IQ Consensus.
  • The Company's expectations for 2017 are:
  • Mid- to high-teens consolidated revenue growth
  • Consolidated EBITDA margin1 of 6.0% to 6.5%
  • "Our businesses continue to win novel drudgery across the portfolio, with broad project wins driving Company backlog above $4 billion for the first time in their Company's 95-year history. For the fifth consecutive quarter, Construction segment backlog finished above the $1-billion mark"
  • 7:00 am Xylem beats by $0.02, reports revs in-line; guides FY17 EPS above consensus, revs above consensus (XYL) :

  • Reports Q2 (Jun) earnings of $0.59 per share, excluding non-recurring items, $0.02 better than the Capital IQ Consensus of $0.57; revenues rose 24.9% year/year to $1.16 bln vs the $1.17 bln Capital IQ Consensus.
  • Co issues raised guidance for FY17, sees EPS of $2.30-2.40 from $2.23-2.38, excluding non-recurring items, vs. $2.31 Capital IQ Consensus Estimate; raises FY17 revs of $4.65-4.70 bln from $4.50-4.60 bln vs. $4.6 bln Capital IQ Consensus Estimate.
  • Orders exceeded $1.2 billion in the second quarter, growing eight percent organically. On a pro forma organic basis, Xylem projects revenue growth of three to four percent. On an organic basis, which excludes the repercussion of acquisitions and the repercussion of alien exchange translation, Xylem's revenue growth is now anticipated to exist in the gain of two to three percent. "Looking ahead, they maintain solid plans and are operating in improving discontinue markets, which reinforce their confidence in their talent to deliver solid growth and margin expansion in line with their improved guidance for the complete year."
  • 7:00 am Bristol-Myers announces that the FDA has approved Opdivo (nivolumab) injection for the treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed with a fluoropyrimidine, oxaliplatin, and irinotecan (BMY) :

    Approval for this indication has been granted under accelerated approval based on overall response rate (:ORR) and duration of response.

  • In the CheckMate -142 trial, among patients who received prior treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, 28% responded to treatment with Opdivo.
  • Among these responders, the median duration of response was not reached
  • Opdivo is associated with the following Warnings and Precautions including immune-mediated: pneumonitis, colitis, hepatitis, endocrinopathies, nephritis and renal dysfunction, skin adverse reactions, encephalitis, other adverse reactions; infusion reactions; and embryo-fetal toxicity.
  • 7:00 am Asian Markets Close: Nikkei +0.3%, Hang Seng +0.8%, Shanghai +0.6% (:SUMRX) :

    Equity indices in the Asia-Pacific region ended Tuesday on a higher note. Regional economic data included below-consensus Manufacturing PMI readings from India and Japan while China's Caixin Manufacturing PMI beat expectations. The People's Bank of China reportedly uncovered operational violations at 40 Chinese banks. The banks maintain up to six months to correct the issues. In Japan, Chief Cabinet Secretary Yoshihide Suga confirmed that Prime Minister Shinzo Abe plans to reshuffle his cabinet on August 3. The Reserve Bank of Australia left its cash rate unchanged at 1.50%, as expected. The central bank notable that the relative energy of the Australian dollar results from weakness in the U.S. dollar. The Reserve Bank of India will meet overnight.

  • In economic data:
  • Japan's July Manufacturing PMI 52.1 (expected 52.2; terminal 52.2)
  • China's July Caixin Manufacturing PMI 51.1 (consensus 50.4; terminal 50.4)
  • India's Nikkei July Manufacturing PMI 47.9 (expected 50.8; terminal 50.9)
  • South Korea's July Nikkei Manufacturing PMI 49.1 (last 50.1)
  • Australia's July AIG Manufacturing Index 56.0 (last 55.0)
  • South Korea's July CPI +0.2% month-over-month (last -0.1%); +1.9% year-over-year (consensus 2.0%; terminal 1.9%). July trade surplus narrowed to KRW10.65 billion from KRW10.77 billion. July Imports +14.5% year-over-year (last 19.8%) and July Exports +19.5% year-over-year (last 13.6%)
  • ---Equity Markets---

  • Japan's Nikkei edged up 0.3%. Toshiba spiked 11.0% while Nitto Denko, Yamato Holdings, Teijin, Sumitomo Mitsui Financial, T&D Holdings, Dentsu, Sumitomo Mitsui, Sony pecuniary Holdings, and Mitsubishi advanced between 1.8% and 3.7%.
  • Hong Kong's Hang Seng climbed 0.8%, nearing its high from 2015. Financials ended in the lead with Ping An Insurance, China Life Insurance, BoC Hong Kong, Bank of China, Bank of East Asia, China Construction Bank, ICBC, and Hang Seng Bank climbed between 0.8% and 4.1%. On the downside, Geely Automobile lost 1.8%.
  • China's Shanghai Composite slipped from its high in afternoon action, but charged to a fresh high into the close, adding 0.6%. Shanghai Jin Jiang International Industrial Investment, Shanghai Lujiazui Finance & Trade Zone Development, Anhui Expressway, Bestsun Energy, and Beijing Teamsun Technology gained between 4.5% and 5.1%.
  • India's Sensex ticked up 0.2% with more than half of its components moving higher. Hero MotoCorp, Maruti Suzuki, and Mahidra&Mahindra gained between 1.8% and 2.1% while tech consultants were mixed. Wipro gained 1.8%, Tata Consultancy shed 0.2%, and Infosys lost 0.6%. Lupin was the weakest performer, falling 1.4%.
  • ---FX---

  • USDJPY +0.2% to 110.45
  • USDCNY -0.1% to 6.7203
  • USDINR -0.1% to 64.08
  • 6:57 am Glatfelter Co misses by $0.13, misses on revs (GLT) :

  • Reports Q2 (Jun) loss of $0.06 per share, excluding non-recurring items, $0.13 worse than the Capital IQ Consensus of $0.07; revenues fell 4.7% year/year to $387.3 mln vs the $394.84 mln Capital IQ Consensus.
  • In the Composite Fibers and Advanced Airlaid Materials business units, net sales increased by 1.4% and 4.9%, respectively, on a constant currency basis.
  • Specialty Papers' net sales declined 8.6% in the quarter-over-quarter comparison.
  • "We had solid growth in shipping volumes and improved performance in their engineered materials businesses during the quarter," said Dante C. Parrini, Chairman and Chief Executive Officer. "However, their overall results for the quarter were lower than expected due to continued weakness in Specialty Papers' markets. Volumes in their Composite Fibers business strengthened, increasing 3% over terminal year's second quarter and 4% year-to-date, driven by improved claim across most product lines and particularly wall cover products. While they are seeing even growth in the Composite Fibers business, they remain focused on their cost optimization initiatives that are expected to deliver $10 million in cost savings in 2017. The Advanced Airlaid Materials business performed well delivering top-line growth and improved profitability, as operating income increased 11% over the prior-year quarter and 10% for the year. For the balance of 2017, they await continued growth in shipments and stalwart operating performance from their engineered materials businesses. They furthermore peer forward to the incremental growth expected from their novel Fort Smith, Arkansas facility coming on-line later this year with commercial shipments rise early 2018."
  • 6:56 am Louisiana-Pacific reports EPS in-line, revs in-line (LPX) :

  • Reports Q2 (Jun) earnings of $0.58 per share, excluding non-recurring items, in-line with the Capital IQ Consensus of $0.58; revenues rose 19.2% year/year to $694 mln vs the $700.73 mln Capital IQ Consensus. 
  • "Despite concerns about lot availability and labor shortages constraining novel construction, they are encouraged by the year-over-year extend in single-family starts...In the second half of the year, they will remain focused on sustainable improvements and growth in sum of their businesses, including continued siding growth and launching of novel specialty products."
  • 6:54 am Mosaic beats by $0.06, reports revs in-line (MOS) :

  • Reports Q2 (Jun) earnings of $0.29 per share, excluding $0.01 in non-recurring items, $0.06 better than the Capital IQ Consensus of $0.23; revenues rose 4.7% year/year to $1.75 bln vs the $1.75 bln Capital IQ Consensus.
  • Guidance: Total sales volumes for the Phosphates segment are expected to gain from 2.2 to 2.5 mln tonnes for the third quarter of 2017, compared to 2.5 mln tonnes terminal year. Total sales volumes for the Potash segment are expected to gain from 1.9 to 2.2 mln tonnes for the third quarter of 2017, compared to 2.2 mln tonnes terminal year. For calendar 2017, Mosaic now expects: Canadian resource taxes to gain from $90 to $110 mln, narrowed from previous guidance of $85 to $135 mln. Brine management costs to gain from $150 to $160 mln, down from $160 to $180 mln. Capital expenditures in the gain of $800 to $850 mln down from a gain of $800 to $900 mln. Potash sales volumes in the gain of 8.1 to 8.6 mln tonnes, narrowed from 8.0 to 8.75 mln tonnes. Phosphates sales volumes in the gain of 9.5 to 10 mln tonnes, narrowed from 9.5 to 10.25 mln tonnes. International Distribution sales volumes in the gain of 6.75 to 7.25 mln tonnes, down from 7.0 to 7.5 mln tonnes.
  • 6:51 am Xerox beats by $0.07, misses on revs; narrows FY17 EPS in-line (XRX) :

  • Reports Q2 (Jun) earnings of $0.87 per share, excluding non-recurring items, $0.07 better than the Capital IQ Consensus of $0.80; revenues fell 8.1% year/year to $2.57 bln vs the $2.6 bln Capital IQ Consensus.
  • Co issues in-line guidance for FY17, sees EPS of $3.20-3.44 (prior: $3.2-3.52) vs. $3.34 Capital IQ Consensus Estimate.
  • Xerox continues to await to generate operating cash flux from continuing operations of $700 to $900 million and free cash flux from continuing operations of $525 to $725 million in 2017.
  • "We are pleased with the stalwart operating margins and cash flux they delivered, as well as the continued progress on their Strategic Transformation initiatives," said Jeff Jacobson, Xerox chief executive officer. "This resulted in solid operating results despite revenue declines, which were driven by lower paraphernalia sales as they transition to the recently launched ConnectKey portfolio." Jacobson added, "The novel product line-up has been met with enthusiasm by customers, partners and industry experts, fueling their confidence in improving revenue trends later this year and into next."
  • 6:51 am Intl Game Tech. PLC misses by $0.17, beats on revs; reaffirms EBITDA guidance (IGT) :

  • Reports Q2 (Jun) earnings of $0.15 per share, excluding non-recurring items, $0.17 worse than the Capital IQ Consensus of $0.32; revenues fell 5.1% year/year to $1.22 bln vs the $1.2 bln Capital IQ Consensus. The constant currency decline of 5% is mostly attributable to the novel Lotto concession dynamics and the sale of Double Down Interactive LLC, which closed on June 1, 2017. Global lottery same-store revenue, excluding Italy, grew 2.6% in the second quarter, on top of stalwart North America jackpot activity in the prior year period. Excluding multi-state jackpot games, global lottery same-store revenue grew 4.9%. In Italy, late numbers activity was lower than the elevated levels in the second quarter of 2016. Excluding late numbers, Italy Lotto wagers increased 1%. Gaming service revenue was primarily impacted by the sale of DoubleDown. The global installed basis continues to grow, rising 2,701 units from the prior-year period. Global gaming product revenue increased 5% over the second quarter of 2016 driven by 25% growth in terminal sales that was partially offset by lower systems sales. The Company shipped 8,884 gaming machines worldwide during the second quarter, led by stalwart replacement unit demand.
  • The Company is maintaining its outlook for adjusted EBITDA of $1,600-$1,680 million, and the expectation for net debt remains $6,950-$7,150 million for the complete year 2017 period. The outlook for maintenance and growth capital expenditures has been reduced by $50 million to $575-$625 million.
  • 6:51 am TransUnion prices 22.5 mln (upsized from 20 mln shares) common stock offering by selling stockholders; charge not disclosed (TRU) :  

    6:50 am CONSOL Energy beats by $0.07, beats on revs; updates guidance (CNX) :

  • Reports Q2 (Jun) earnings of $0.17 per share, $0.07 better than the Capital IQ Consensus of $0.10; revenues rose 202.8% year/year to $865.95 mln vs the $678.79 mln Capital IQ Consensus.
  • During the second quarter of 2017, CONSOL's E&P Division sold 92.2 Bcfe, or a diminish of 7% from the 99.3 Bcfe sold in the year-earlier quarter, which resulted primarily from both timing delays associated with the TIL schedule and from the company selling approximately 3.0 Bcfe of production related to the net developed acres located in Doddridge and Wetzel counties, West Virginia. As stated terminal quarter, the company expected to TIL three pads in the second quarter; however, due to operational delays, the company ended up turning-in-line one pad. Therefore, the company expects to TIL five pads in the third quarter, which includes the two delayed pads from the second quarter. Lastly, the diminish of 3.0 Bcfe of production associated with the West Virginia sale was retroactive starting on January 1, 2017 through May 31, 2017.
  • Guidance: 
  • CONSOL Energy maintains its E&P Division production guidance for 2017 of approximately 420-440 Bcfe, while increasing its total E&P capital expenditures in 2017 to approximately $620-$645 million, compared to previous guidance of approximately $555 million. The extend in 2017 capital is driven primarily by three areas: additional capital associated with operational challenges in the second quarter, service cost inflation related to pressure pumping services, and continuous improvement progress. The continuous improvement progress is driven by improved drilling cycle times resulting in the company expecting to drill nine additional wells in 2017 and by modifying production protocols, both of which are expected to extend 2018 production to 520-550 Bcfe, compared to previous guidance of 490-520 Bcfe. Also, the company has added another layer of hedges for the expected incremental production in 2018 to abet lock in returns and cash flows.
  • 6:47 am Extended stay America reports EPS in-line, misses on revs; lowers FY17 revs guidance (STAY) :

  • Reports Q2 (Jun) earnings of $0.31 per share, in-line with the Capital IQ Consensus of $0.31; revenues rose 1.7% year/year to $338.36 mln vs the $342.7 mln Capital IQ Consensus.
  • Comparable Hotel RevPAR for the three months ended June 30, 2017 grew 2.4% over the identical epoch in 2016, driven by an improvement in occupancy of 220 basis points to 78.9% while impartial Daily Rate ("ADR") declined slightly by 0.5%. Comparable Hotel RevPAR for the six months ended June 30, 2017 grew 2.3% to $49.44 driven by a 150 basis point extend in occupancy and a 0.2% extend in ADR compared to the identical epoch in 2016.
  • Co lowers guidance for FY17, sees FY17 revs of $1.278-1.303 bln (Prior $1.285-1.31 bln) vs. $1.3 bln Capital IQ Consensus Estimate; continues to behold comparable RevPAR +1.5-3.5%
  • 6:47 am Houston American Energy provides production information on its Johnson condition #1H well and provided an update with respect to the status of its drilling and completion operations in Reeves County, Texas (HUSA) :

    On July 28, 2017, the operator on the Johnson condition well began the process of shutting in the well pending completion of production handling facilities and tying into the gas sales line, which is anticipated within the next two weeks.

  • Prior to shut in, the latest daily flowback report indicated production rates of 351 barrels of oil per day and 4,269 mcf of natural gas per day, or a combined 1,062 barrels of oil equivalent per day. 
  • The company's second Reeves County well, the O'Brien #3H, reached total depth on July 1, 2017.
  • The well, with a 4,575 foot horizontal leg in the Upper Wolfcamp A shale, is scheduled to commence hydraulic fracturing operations during the second half of August 2017. 
  • We await to behold meaningful improvements in their production, revenue and profitability by the discontinue of Q3 2017."
  • 6:47 am Pfizer beats by $0.01, misses on revs; raises low discontinue of FY17 EPS, reaffirms FY17 revs guidance (PFE) :

  • Reports Q2 (Jun) earnings of $0.67 per share, excluding non-recurring items, $0.01 better than the Capital IQ Consensus of $0.66; revenues fell 1.9% year/year to $12.9 bln vs the $13.08 bln Capital IQ Consensus. reflecting a slight operational decline of $48 million and the unfavorable repercussion of alien exchange of $202 million, or 2%. Excluding the revenues for HIS in both periods and the unfavorable repercussion of alien exchange, second-quarter 2017 revenues increased by $248 million, or 2%. Second-quarter 2017 revenues excluding the net repercussion of acquisitions and divestitures completed in 2016 and the first six months of 2017 were flat operationally compared to second-quarter 2016.
  • Co issues guidance for FY17, raises EPS to $2.54-2.60 from $2.50-2.60, excluding non-recurring items, vs. $2.55 Capital IQ Consensus Estimate; reaffirms FY17 revs of $52-54 bln vs. $52.78 bln Capital IQ Consensus Estimate.
  • 6:47 am Waddell & Reed beats by $0.01, reports revs in-line (WDR) :

  • Reports Q2 (Jun) earnings of $0.39 per share, excluding non-recurring items, $0.01 better than the Capital IQ Consensus of $0.38; revenues fell 10.2% year/year to $286.7 mln vs the $285.25 mln Capital IQ Consensus.
  • The second quarter of 2017 excluded a tax freight of $8.9 million ($0.11 per diluted share) related to the implementation of novel accounting guidance regarding the tax consequences of share-based payments. Assets under management ended the second quarter of 2017 at $80.4 billion, decreasing less than 1% compared to the prior quarter and decreasing 7% compared to the second quarter of 2016.
  • 6:44 am Tata Motors domestic sales grows by 13% in July 2017 (TTM) :

  • The overall commercial vehicles sales in July 2017, in the domestic market were at 27,842 nos. higher by 15% over July 2016, due to ramp-up of BS4 production, across segments. The Company furthermore passed on the benefits of GST to consumers by reducing the prices of its vehicles across sum commercial vehicle segments.
  • In July 2017, Tata Motors passenger vehicles, in the domestic market, recorded sales at 14,933 nos., with a growth of 10%, over 13,547 units, in July 2016, due to continued stalwart claim for the Tata Tiago and the Tata Tigor. While the car segment marginally degrew by 1% at 12,125 nos., the UV segment grew by 110% at 2,808 nos., due to stalwart claim for Tata HEXA.
  • 6:44 am Kamada reports EPS in-line, misses on revs; reaffirms FY17 revs guidance (KMDA) :

  • Reports Q2 (Jun) earnings of $0.13 per share, in-line with the Capital IQ Consensus of $0.13; revenues rose 70.7% year/year to $32.55 mln vs the $33.3 mln two analyst estimate.
  • Co reaffirms guidance for FY17, sees FY17 revs of $100 mln vs. $101.31 mln two analyst estimate.
  • Upcoming Milestones:
  • PDUFA date of August 29, 2017 for the completion of the review of the BLA for Anti-Rabies IgG therapy.
  • Expect to receive FDA approval to conduct a pivotal side 3 affliction for inhaled AAT.
  • Last patient enrolled in February 2017 in the Company's Type-1 Diabetes side 2 trial; top-line results anticipated in the second half of 2017.
  • Completed patient recruitment in the Company's lung transplantation side 2 trial; await to maintain an interim report from this affliction in the second half of 2017.
  • Anticipate submitting Clinical affliction Application for IV AAT in GvHD in Europe in the second half of 2017, and initiating the combined U.S. and European affliction in 2018.
  • As of June 30, 2017, the Company had cash, cash equivalents and short term investments of $26.9 million, compared with $28.6 million as of December 31, 2016.
  • 6:41 am Mobile Mini appoints Van Welch to Executive Vice President & CFO, efficient August 31, 2017 (MINI) : Most recently, Mr. Welch held the position of Executive Vice President and Chief pecuniary Officer at Willbros Inc. (WG), and previously served in senior finance roles at KBR Group.

    6:41 am WestJet reports Q2 results (WJAFF) :

  • Co reported Q2 EPS of CAD 0.41 vs CAD 0.30 terminal year; revs +11.1% YoY to CAD 1.055 bln.
  • WestJet achieved its 49th consecutive quarter of profitability and flew a record 5.9 million guests. Based on the trailing twelve months, the airline achieved a return on invested capital of 9.8 per cent, compared with the 10.0 per cent reported in the previous quarter.
  • 6:41 am Edge Therapeutics reports Q2 net loss, in-line (EDGE) :

  • Q2 EPS ($0.44) vs ($0.44) Capital IQ Consensus Estimate
  • "NEWTON 2, their side 3 clinical study designed to uphold potential registrations throughout the world for EG-1962 as a treatment for aneurysmal subarachnoid hemorrhage (aSAH) delivered via external ventricular drain, is ongoing. They peer forward to the study's pre-planned futility analysis in late-2017, top-line efficacy results from the interim analysis in the first quarter of 2018 and, if needed, top-line results from the complete study in late-2018. They are furthermore evaluating alternative routes of administration to expand the population of aSAH patients who may benefit from EG-1962. This includes their ongoing controlled study of EG-1962 delivered directly into the basal cisterns of the brain in good-grade patients with ruptured brain aneurysms. In addition, during the quarter, they initiated evolution activities for lumbar administration of EG-1962. There remains a significant unmet exigency to better outcomes in patients with aSAH, and they peer forward to receiving EG-1962 data in the coming quarters."
  • 6:40 am character Systems beats by $0.02, beats on revs; lowers FY18 EPS in-line, reaffirms FY18 revs guidance (QSII) :

  • Reports Q1 (Jun) earnings of $0.17 per share, excluding non-recurring items, $0.02 better than the Capital IQ Consensus of $0.15; revenues rose 7.1% year/year to $130.9 mln vs the $126.75 mln Capital IQ Consensus.
  • Co issues guidance for FY18, sees EPS of $0.62-0.70 (prior: $0.66-0.74), excluding non-recurring items, vs. $0.70 Capital IQ Consensus Estimate; sees FY18 revs of $512-530 mln vs. $521.93 mln Capital IQ Consensus Estimate.
  • Lowering FY18 EPS guidance to account for incremental investments in the EagleDream Health platform. 
  • "Fiscal 2018 is off to a very solid start, as they saw stalwart pecuniary results and continued to compose progress on their strategic plan. During the quarter, they leveraged their platform as a service strategy to further enhance their solution offerings and enhance the value they bring to their clients. Furthermore, the significant modifications we've made to their business model will simplify the process and extend the ease of partnering with NextGen going forward. I feel very confident in their position within the market and their talent to drive bookings growth in the back half of fiscal 2018," commented Rusty Frantz, President and Chief Executive Officer of character Systems, Inc.
  • 6:38 am Horizon Global beats by $0.17, beats on revs; guides Q3 EPS below consensus, revs above consensus; raises FY17 EPS above consensus, reaffirms FY17 revs guidance; acquires Best Bars Ltd. (HZN) :

  • Reports Q2 (Jun) adj. earnings of $0.84 per share, $0.17 better than the Capital IQ Consensus of $0.67; revenues rose 51.1% year/year to $253.6 mln vs the $241.08 mln Capital IQ Consensus.
  • Co issues mixed guidance for Q3, sees EPS of $0.35-0.40, excluding non-recurring items, vs. $0.44 Capital IQ Consensus Estimate; sees Q3 revs of $225-235 mln vs. $220.78 mln Capital IQ Consensus Estimate.
  • Co issues guidance for FY17, raises EPS to $1.04-1.14, excluding non-recurring items, vs. $0.98 Capital IQ Consensus Estimate; reaffirms FY17 rev +30-35%.
  • Regionally, Horizon Americas delivered stalwart growth in e-commerce and aftermarket channels as sales recovered from order delays in the first quarter of 2017. Horizon Asia-Pacific experienced double-digit organic growth by expanding into industrial products. As a whole, the Company's operating profit more than doubled as a result of leverage from increased sales and operational improvements." "We reiterate their confidence in achieving 9 million in expected synergies during 2017 due to their Westfalia integration efforts. The momentum in Horizon Europe-Africa continues to build, and they await to realize ongoing benefits from the business in the back half of 2017 and beyond.
  • "We are furthermore pleased to publish their recently completed acquisition of Best Bars Limited, an established leader in the towing and trailering industry in novel Zealand. Best Bars is now Part of Horizon Asia-Pacific, and they await this acquisition to uphold the growth of their global OE business."
  • 6:38 am Eaton misses by $0.01, reports revs in-line; guides Q3 EPS in-line; narrows FY17 EPS in-line (ETN) :

  • Reports Q2 (Jun) earnings of $1.15 per share, $0.01 worse than the Capital IQ Consensus of $1.16; revenues rose 1.0% year/year to $5.13 bln vs the $5.14 bln Capital IQ Consensus.
  • Co issues in-line guidance for Q3, sees EPS of $1.20-1.30 vs. $1.28 Capital IQ Consensus Estimate.
  • Co issues narrows guidance for FY17, sees EPS of $4.50-4.70 from $4.45-4.75 vs. $4.65 Capital IQ Consensus Estimate.
  • "Operating margins in the second quarter were 17.5 percent, and excluding restructuring costs of $11 million, 18.1 percent...Margins increased 0.5 percentage point over the first quarter of 2017, excluding restructuring costs in both quarters."
  • 6:36 am Versum Materials beats by $0.08, beats on revs; raises FY17 guidance (VSM) :

  • Reports Q3 (Jun) earnings of $0.52 per share, excluding non-recurring items, $0.08 better than the Capital IQ Consensus of $0.44; revenues rose 19.8% year/year to $290.8 mln vs the $265.64 mln Capital IQ Consensus.
  • Adjusted EBITDA for the fiscal third quarter ended June 30, 2017 was $97.7 million versus $80.3 million in the identical quarter a year ago, a 21.7% extend year on year. stalwart volumes in both DS&S and Materials coupled with modestly favorable currency were partially offset by expected higher operating and selling and administrative costs associated with becoming an independent company and unfavorable price/mix in the Materials segment, primarily in Process Materials.
  • Co raises guidance for FY17, sees FY17 revs of $1.09-1.12 bln (Prior $1.02-1.065 bln) vs. $1.07 bln Capital IQ Consensus Estimate; sees Adj-EBITDA of $365-375 mln (Prior $340-355 mln)
  • 6:36 am Denison Mining reports a novel high-grade uranium intersection in basement rocks from the first pocket completed as Part of the summer 2017 drilling program at the Waterbury Lake property (DNN) :

    Drill pocket WAT-17-443 intersected 1.1% eU3O8 over 0.8 metres (from 296.9 to 297.7 metres) ~1.5 kilometres to the northeast of the property's J Zone uranium deposit.

  • The high-grade mineralization occurs immediately below a broader 10.3 metre mineralized interval (from 282.8 to 293.1 metres) with an impartial grade of 0.15% eU3O8.
  • The mineralization is open in sum directions and follow-up drilling is presently underway.
  • 6:36 am Ingredion beats by $0.03, misses on revs; reaffirms FY17 EPS guidance (INGR) :

  • Reports Q2 (Jun) earnings of $1.89 per share, $0.03 better than the Capital IQ Consensus of $1.86; revenues rose 0.1% year/year to $1.46 bln vs the $1.5 bln Capital IQ Consensus.
  • Co reaffirms guidance for FY17, sees EPS of $7.50-7.80, excluding non-recurring items, vs. $7.58 Capital IQ Consensus Estimate.
  • "We continue to deliver shareholder value with another stalwart quarter, including solid operating income and earnings per share growth. estimable operating efficiency, the repercussion of acquisitions, and higher specialty volumes more than offset headwinds in South America," said Ilene Gordon, chairman, president and chief executive officer. "Operating income in North America reached record levels, but was lower in South America due to macroeconomic headwinds and the temporary interruption of manufacturing activities in Argentina associated with the implementation of a novel labor agreement."
  • 6:35 am Harris reports EPS in-line, beats on revs; guides FY18 EPS below consensus, revs in-line (HRS) :

  • Reports Q4 (Jun) earnings of $1.49 per share, excluding non-recurring items, in-line with the Capital IQ Consensus of $1.49; revenues rose 0.6% year/year to $1.54 bln vs the $1.52 bln Capital IQ Consensus.
  • Co issues guidance for FY18, sees EPS of $5.85-6.05, excluding non-recurring items, vs. $6.08 Capital IQ Consensus Estimate; sees FY18 revs of $6.02-6.14 bln vs. $6.07 bln Capital IQ Consensus Estimate. Harris expects fiscal 2018 free cash flux in a gain of $850 - 900 million.
  • "Our fiscal 2017 performance, including higher revenue and stalwart orders in the fourth quarter, positions us well for returning to growth in fiscal 2018 and accelerating in the medium term...We enter the year at an inflection point, with positive momentum and a continued focus on generating organic growth, driving flawless execution, maintaining margins through operational excellence, and deploying capital in a balanced manner."
  • 6:34 am Epizyme and US Oncology Research publish a collaboration to screen and identify relapsed or refractory follicular lymphoma and diffuse large B-cell lymphoma patients with EZH2 mutations (EPZM) :

    Under the collaboration, US Oncology Research will implement a part screening protocol in 68 locations in the U.S. to identify relapsed or refractory FL and DLBCL patients with tumors demeanor EZH2 mutations who may exist candidates for enrollment in Epizyme's ongoing side 2 clinical trial.

  • US Oncology Research will direct identified patients to the tazemetostat side 2 clinical affliction for protocol screening and potential enrollment into the trial. Sites began screening patients in July 2017.
  • 6:34 am Crestwood Equity Partners reports Q2 (Jun) results, beats on revs; updates outlook (CEQP) :

  • Reports Q2 (Jun) loss of $0.28 per share, may not exist comparable to the Capital IQ Consensus of ($0.07); revenues rose 41.3% year/year to $850.3 mln vs the $706.34 mln Capital IQ Consensus.
  • Second quarter 2017 Adjusted EBITDA of $97.3 million, compared to $106.5 million in the second quarter 2016; Adjusted EBITDA for the second quarter 2017 reflects the deconsolidation of Stagecoach Gas Services compared to the second quarter 2016 which included 100% contribution in April and May 2016
  • Updated Outlook:
  • Adjusted EBITDA of $380 million to $400 million
  • Distributable cash flux of $210 million to $230 million
  • Growth project capital spending and joint venture contributions unchanged in the gain of $225 million to $250 million
  • 6:33 am character Systems to acquire EagleDream Health, a cloud-based analytics company, for $26 mln in cash (QSII) :

    With its vendor-agnostic platform for managing value-based care, EagleDream Health empowers organizations with intuitive analytics and actionable intelligence to achieve successful population health management.

  • The proposed acquisition will enable NextGen Healthcare to enhance the freight relish and extend patient engagement for ambulatory clinics and health systems while reducing the per capita cost of healthcare and improving the work-life poise for clinicians and staff.
  • The transaction is expected to close in the current quarter.
  • 6:33 am Thomson Reuters beats by $0.09, reports revs in-line; raises FY17 EPS above consensus; reaffirms revenue (TRI) :

  • Reports Q2 (Jun) earnings of $0.60 per share, excluding non-recurring items, $0.09 better than the Capital IQ Consensus of $0.51; revenues rose 0.5% year/year to $2.78 bln vs the $2.78 bln Capital IQ Consensus, recurring revenues and contributions from acquisitions were mostly offset by the repercussion of alien currency. At constant currency, revenues increased 2%. Operating profit was essentially unchanged as slightly higher revenues and lower expenses, which reflected savings from the company's simplification initiatives, were offset by the unfavorable repercussion of honest value adjustments associated with alien currency derivatives embedded in inevitable customer contracts.
  • Co issues guidance for FY17, raises EPS to $2.40-2.45 from $2.35, excluding non-recurring items, vs. $2.35 Capital IQ Consensus Estimate. Based on the results of the first half of the year, the company raised its full-year outlook for adjusted EBITDA margin and adjusted EPS. The company reaffirmed its full-year outlook for revenue growth and free cash flow. For the full-year 2017, the company currently expects: Low single-digit revenue growth Adjusted EBITDA margin to gain between 29.3% - 30.3% - up from previous guidance of 28.8% - 29.8% Free cash flux to gain between $0.9 billion and $1.2 billion, which reflects cash payments in 2017 relating to the fourth-quarter 2016 charges, the $500. 
  • 6:33 am Willbros Group CFO Van A. Welch to resign after accepting a similar position in a different industry efficient August 30 (WG) :  

    6:32 am Radian Group beats by $0.07, beats on revs (RDN) :

  • Reports Q2 (Jun) earnings of $0.48 per share, excluding non-recurring items, $0.07 better than the Capital IQ Consensus of $0.41; revenues rose 4.9% year/year to $302.91 mln vs the $299.07 mln Capital IQ Consensus.
  • New MI business written increases 11% and MI in favor increases 8% year-over-year.
  • Book value per share grows 3% and tangible bespeak value per share grows 12% year-over-year.
  • "I am pleased to report on their stalwart operating performance in the second quarter, including a 26% extend in adjusted diluted net operating income per share, 8% growth in their mortgage insurance in favor and a 12% extend in tangible bespeak value per share," said Radian's Chief Executive Officer Rick Thornberry. "I continue to exist excited about the opportunities ahead for Radian. They maintain a unique opportunity to leverage their market-leading Mortgage Insurance franchise combined with their core capabilities across the Services segment to deliver high-value and relevant products and services. Successfully capturing these opportunities will enable us to further deepen customer relationships, grow sustainable revenues and profitability and extend stockholder value."
  • 6:32 am Glowpoint completes debt recapitalization, resulting in an extend of approx. $8.7 mln to stockholders' equity; therefore, the co expects to meet the continued listing standards of the NYSE (GLOW) :  

    6:32 am Columbus McKinnon beats by $0.19, beats on revs (CMCO) :

  • Reports Q1 (Jun) earnings of $0.51 per share, $0.19 better than the Capital IQ Consensus of $0.32; revenues rose 36.7% year/year to $203.7 mln vs the $190.62 mln Capital IQ Consensus.
  • Backlog increased 12.2% to $173.3 million as of June 30, 2017 compared with March 31, 2017.
  • "We anticipate that sales in the fiscal second quarter will exist comparable with the quarter just completed, although sales coalesce will provide a little lower operating income. In the meantime, they remain focused on their near-term priorities: the integration of STAHL, strengthening their core business for greater profitability, further leveraging their Magnetek technology for greater revenue potential and reducing debt."
  • 6:31 am Holly Energy Partners misses by $0.10, misses on revs (HEP) :

  • Reports Q2 (Jun) earnings of $0.36 per share, $0.10 worse than the two analyst assess of $0.46; revenues rose 15.0% year/year to $109.14 mln vs the $113.12 mln Capital IQ Consensus.
  • Distributable cash flux was $60.9 million for the quarter, up $5.2 million, or 9.3% compared to the second quarter of 2016. HEP announced its 51stconsecutive distribution extend on July 27, 2017, raising the quarterly distribution from $0.62 to $0.6325 per unit, which represents an extend of 8.1% over the distribution for the second quarter of 2016, exceeding HEP's distribution growth target of 8%.
  • 6:27 am WestRock acquires Hannapak a provider of folding cartons to a variety of markets, including beverage, food, confectionary, and healthcare; WestRock will pay AUD$75 mln in cash (WRK) :  

    6:22 am Corvel reports Q1 results (CRVL) :

  • Q1 EPS $0.46 vs. $0.38 terminal year; rev +7% to $138 mln (no estimates).
  • Revenue growth for the quarter was driven by an extend in the Company's claims management services. Network Solutions, including Pharmacy benefit Management (PBM) programs, furthermore had improved results driven by CorVel's value-added performance for clients. Payors physiognomy increasing pressure to abet accommodate inflating medical costs which has increased interest in the Company's medical review and provider management services. The Company recently announced the release of an advanced claims management workstation for the insurance carrier marketplace.
  • 6:18 am ICHOR Corporation commences public offering of 5.5 mln ordinary shares by selling shareholders (ICHR) :  

    6:18 am Freeport-McMoRan sells inevitable interest in the Gulf of Mexico Outer Continental Shelf to Cox Oil Offshore; terms not disclosed (FCX) :  

    6:13 am On The Wires (:WIRES) :

  • Visa (V) announced its uphold of the novel global QR Code Payment Specifications from EMVCo, the global technical carcass that manages the EMV Specifications. The specifications cover consumer-presented and merchant-presented QR code expend cases for digital payment acceptance. QR codes are two-dimensional machine-readable barcodes, used to facilitate mobile payments at the point-of-sale.
  • Cellcom Israel Ltd. (CEL) announced that following the previously reported amendment to the Company's cellular license in relation to the requirement that Israeli citizens and residents from among the Company's founding shareholders hold at least 5% of the Company's outstanding shares and other means of control, as of July 2017, the Israeli Ministry of Communications amended the Company's cellular license so as to postpone the application of such requirement until October 31, 2017.
  • TransAlta Corporation (TAC) and TransAlta Renewables responded to Fortescue Metals Group Limited's (FSUMF) view that the South Hedland Power Station has not yet achieved commercial operation. sum the conditions to establishing that commercial operations maintain been achieved under the terms of the power purchase agreement with FMG maintain been satisfied in full. These conditions comprise receiving a commercial operation certificate, successfully completing and passing inevitable test requirements, and obtaining sum permits and approvals required from the North West Interconnected System and government agencies. The South Hedland Power Station is fully operational and able to meet sum of FMG's requirements under the terms of the PPA.
  • 6:11 am MDC Holdings beats by $0.03, beats on revs (MDC) :

  • Reports Q2 (Jun) earnings of $0.64 per share, $0.03 better than the Capital IQ Consensus of $0.61; revenues rose 13.6% year/year to $648.97 mln vs the $623.95 mln Capital IQ Consensus.
  • Selling, generic and administrative expenses as a percentage of home sale revenues improved 40 basis points from 11.3% to 10.9%.
  • Dollar value of net novel orders of $710.6 million versus $722.5 million.
  • Monthly sales absorption pace of 3.41 improved 2%.
  • Ending backlog dollar value up 4% to $1.68 billion from $1.61 billion.
  • Approved 3,342 lots for purchase in 44 communities.
  • Last twelve months return on equity improved 340 basis points to 9.3%.
  • Larry A. Mizel, MDC's Chairman and Chief Executive Officer, stated, "We are pleased to publish their 2017 second quarter results, highlighted by a 26% year-over-year extend in their net income. For the second consecutive quarter, they realized a year-over-year improvement in their backlog conversion rate, which helped to drive a double-digit extend in home sale revenues and improved operating leverage. The improved backlog conversion rate was achieved based on stabilizing build-to-order construction cycle times, which decreased sequentially for the first time in almost two years."
  • 6:10 am Pioneer Energy misses by $0.02, beats on revs; offers Q3 guidance (PES) :

  • Reports Q2 (Jun) loss of $0.21 per share, excluding non-recurring items, $0.02 worse than the Capital IQ Consensus of ($0.19); revenues rose 72.0% year/year to $107.13 mln vs the $105.23 mln Capital IQ Consensus.
  • Q3 Outlook:
  • In the third quarter of 2017, Production Services Segment revenue is estimated to exist up approximately 5% to 10% as compared to the second quarter of 2017. Production Services Segment margin is estimated to exist 24% to 26% of revenues in the third quarter. Drilling rig utilization in the third quarter is estimated to impartial 74% to 77%. Drilling Services Segment margin is expected to exist approximately $8,100 to $8,500 per day in the third quarter.
  • 6:09 am Archrock beats by $0.12, beats on revs (AROC) :

  • Reports Q2 (Jun) loss of $0.03 per share, excluding non-recurring items, $0.12 better than the Capital IQ Consensus of ($0.15); revenues rose 4.2% year/year to $198 mln vs the $196 mln two analyst estimate. 
  • "During the quarter, they grew operating horsepower by 40,000 horsepower, improved condense operations indecorous margin percentage by 200 basis points, and increased EBITDA, as adjusted, $7 million sequentially. They continued to drive novel orders at impressive levels, and in spite of the recent commodity charge pull-back, claim for their services has remained at elevated levels providing visibility of novel starts through 2017 and into 2018." "As they maintain communicated over the past nine months, 2017 is a transition year with the prior cyclical downturn giving route to the expansion they expected in the second half of 2017," continued Childers.
  • "We are confident that expansion is underway and they await to behold solid year-over-year growth in year-end 2017 operating horsepower and complete year aftermarket services revenue."
  • 6:08 am Baytex Energy faith reports Q2 (Jun) results, beats on revs; updates guidance (BTE) :

  • Reports Q2 (Jun) earnings of CC$0.04 per share, may not exist comparable to the Capital IQ Consensus of (CC$0.19); revenues rose 40.2% year/year to CC$274.37 mln vs the CC$259.23 mln solitary analyst estimate.
  • Production increased 5% to impartial 72,812 boe/d (79% oil and NGL) in Q2/2017, as compared to 69,298 boe/d (79% oil and NGL) in Q1/2017. Production in the first half of 2017 averaged 71,065 boe/d. During the second quarter, exploration and evolution capital expenditures totaled $78.0 million, bringing the aggregate spending in the first half of 2017 to $174.6 million. They participated in the drilling of 47 (15.3 net) wells with a 100% success rate during the second quarter.
  • Updated guidance:
  • Reflective of their stalwart operating results in the first half of the year, they are tightening their 2017 production guidance gain to 69,000 to 70,000 boe/d (previously 68,000 to 70,000 boe/d). They are now forecasting full-year 2017 exploration and evolution capital expenditures of $310 to $330 million (previously $325 to $350 million). They are furthermore reducing their guidance for operating expenses by 4% (at the mid-point) to $10.75-$11.25/boe as they continue to drive cost efficiencies in their business.
  • 6:08 am Archrock Partners beats by $0.01, reports revs in-line (APLP) :

  • Reports Q2 (Jun) earnings of $0.08 per share, $0.01 better than the Capital IQ Consensus of $0.07; revenues fell 1.3% year/year to $138.3 mln vs the $137.1 mln Capital IQ Consensus. 
  • EBITDA, as adjusted was $66.9 million for the second quarter of 2017, compared to $61.1 million for the first quarter of 2017 and $71.2 million for the second quarter of 2016.
  • 6:06 am Sequans Communications reports EPS in-line, misses on revs; guides Q3 EPS below consensus, revs below consensus (SQNS) :

  • Reports Q2 (Jun) loss of $0.06 per share, excluding non-recurring items, in-line with the Capital IQ Consensus of ($0.06); revenues rose 33.8% year/year to $13.22 mln vs the $14.48 mln Capital IQ Consensus.
  • Gross margin was 42.1% compared to 47.1% in the first quarter of 2017 and compared to 44.6% in the second quarter of 2016, reflecting an extend in the balance of module sales in the product coalesce in the second quarter of 2017.
  • Co issues downside guidance for Q3, sees EPS of ($0.07-0.05), excluding non-recurring items, vs. ($0.04) Capital IQ Consensus Estimate; sees Q3 revs of $15-17 mln vs. $17.59 mln Capital IQ Consensus Estimate.
  • 6:06 am Air Products beats by $0.06, beats on revs; guides Q4 EPS in-line (APD) :

  • Reports Q3 (Jun) earnings of $1.65 per share, excluding non-recurring items, $0.06 better than the Capital IQ Consensus of $1.59; revenues rose 10.8% year/year to $2.12 bln vs the $2.06 bln Capital IQ Consensus on eight percent higher volumes and five percent favorable energy pass-through, partially offset by two percent unfavorable currency. Volumes were positive across sum three regions, while continued progress on the Jazan project was partially offset by lower LNG activity. Taken together, the Industrial Gas regions increased overall volumes by eight percent. Pricing was flat with the prior year.
  • Co issues in-line guidance for Q4, sees EPS of $1.65-1.70, excluding non-recurring items, vs. $1.67 Capital IQ Consensus Estimate.
  • Co issues in-line guidance for FY17, raises EPS $0.10 to $6.20-6.25, excluding non-recurring items, vs. $6.15 Capital IQ Consensus Estimate. 
  • "We continue to exist optimistic about the future performance of Air Products. They behold significant opportunities to expend their very stalwart poise sheet to invest in their core business and create value for their shareholders. They maintain increased their full-year guidance by $0.10 at midpoint, now representing a 10 percent extend over prior year." 
  • 6:06 am Lumber Liquidators beats by $0.24, beats on revs; comparable store sales +8.8% (LL) :

  • Reports Q2 (Jun) earnings of $0.16 per share, $0.24 better than the Capital IQ Consensus of ($0.08); revenues rose 10.7% year/year to $263.5 mln vs the $256.89 mln Capital IQ Consensus.
  • Net sales in comparable stores increased $21 million, or 8.8%, driven by a 5.3% extend in the number of customers invoiced and a 3.5% extend in the impartial sale.
  • Merchandise sales in comparable stores grew 6.1% in the quarter. Net sales in non-comparable stores increased $4.4 million.
  • The Company did not open any stores during the second quarter of 2017, so total store signify remained at 385 as of June 30, 2017.
  • Dennis Knowles, Chief Executive Officer, commented, "In the quarter, they saw positive results in net revenues, comparable store sales and customer traffic, in addition to indecorous margin expansion which drove positive operating results. Customers maintain responded to the investments that they made to broaden and strengthen their assortment with innovative products, while furthermore ensuring the prerogative coalesce of those products were available in their stores. Although they are pleased with the results in the quarter, they still maintain drudgery to do. Their management team is confident in the potential of their business, and remains dedicated to carrying out the long-term strategy of the Company. They believe that by continuing to drudgery their plan, they will position the Company for long-term profitability and growth."
  • 6:05 am Genesee & Wyoming beats by $0.07, reports revs in-line (GWR) :

  • Reports Q2 (Jun) earnings of $0.80 per share, excluding non-recurring items, $0.07 better than the Capital IQ Consensus of $0.73; revenues rose 7.8% year/year to $540.43 mln vs the $539.59 mln Capital IQ Consensus.
  • North American Operations traffic increased 10,924 carloads, or 2.8%, to 397,047 carloads in the second quarter of 2017. Excluding 11,483 carloads from novel operations, identical railroad traffic decreased 559 carloads, or 0.1%. The traffic diminish was principally due to decreases of 1,873 carloads of metallic ores traffic (primarily in the Mountain West and Coastal regions), 1,839 carloads of petroleum products traffic (primarily in the Northeast and Mountain West regions), 1,695 carloads of metals traffic (primarily in the Southern and Coastal regions), 1,547 carloads of chemicals and plastics traffic (primarily in the Mountain West Region) and 1,514 carloads of pulp and paper traffic (primarily in the Southern and Coastal regions), partially offset by increases of 3,235 carloads of agricultural products traffic (primarily in the Central and Mountain West regions), 2,422 carloads of fritter traffic (primarily in the Northeast and Pacific regions) and 1,380 carloads of minerals and stone traffic (primarily in the Central Region). sum remaining traffic increased by a net 872 carloads.
  • 6:03 am Gener8 Maritime misses by $0.05, misses on revs (GNRT) :

  • Reports Q2 (Jun) loss of $0.11 per share, excluding non-recurring items, $0.05 worse than the Capital IQ Consensus of ($0.06); revenues fell 29.3% year/year to $74.95 mln vs the $76.55 mln two analyst estimate.
  • Increased vessel operating days by 18.0% to 3,352 in the three months ended June 30, 2017 compared to 2,841 in the identical epoch in the prior year. Increased complete fleet "ECO" operating days to 54.2% in the three months ended June 30, 2017, compared to 30.8% in the identical epoch in the prior year.
  • "We continue to engage Important steps to strengthen their platform and poise sheet" said Peter Georgiopoulos, Chairman and Chief Executive Officer of Gener8 Maritime. "In this seasonally weaker rate environment, they remain focused on maximizing their pecuniary flexibility in order to manage their business for the near- and long-term. They continue to dispose of older vessels, streamlining their fleet and focusing on high character tonnage with the best return profile. This strengthens their competitive position in the market. They believe the strategy they are pursuing is prudent and reflects their approach to managing their poise sheet and market exposure."
  • 6:03 am Armada Hoffler Properties reports FFO in-line, misses on revs; lowers FY17 FFO guidance (AHH) :

  • Reports Q2 (Jun) funds from operations of $0.25 per share, in-line with the Capital IQ Consensus of $0.25; revenues rose 10.4% year/year to $26.76 mln vs the $27.18 mln Capital IQ Consensus.
  • Co lowers guidance for FY17, sees FFO of $0.97-0.99 (Prior $0.99-1.03) vs. $0.98 Capital IQ Consensus Estimate.
  • 5:50 am Shanghai...+0.60% (FXI) :  

    5:50 am S&P futures vs honest value: +8.50. Nasdaq futures vs honest value: +32.60. :

    5:50 am European Markets : FTSE...7427.36...+55.40...+0.80%.  DAX...12166...+47.50...+0.40%.

    5:50 am Asian Markets : Nikkei...19986...+60.60...+0.30%.  Hang Seng...27540...+216.20...+0.80%.

    5:26 am Sony beats by JPY 6.53, beats on revs; raises FY18 revs outlook (SNE) :

  • Reports Q1 (Jun) earnings of YEN62.70 per share (Basic EPS was YEN64.03), YEN6.53 better than the Capital IQ Consensus of YEN56.17; revenues rose 15.2% year/year to YEN1858.1 bln vs the YEN1735.86 bln Capital IQ Consensus.
  • Co raises guidance for FY18, sees FY18 revs of YEN8300 bln (Prior YEN8000 bln) vs. YEN8021.31 bln Capital IQ Consensus Estimate.
  • 5:05 am Allot Comms reports EPS in-line, beats on revs; reaffirms FY17 revs guidance (ALLT) :

  • Reports Q2 (Jun) loss of $0.07 per share, excluding non-recurring items, in-line with the Capital IQ Consensus of ($0.07); revenues fell 15.1% year/year to $19.52 mln vs the $19.2 mln Capital IQ Consensus.
  • Co reaffirms guidance for FY17, sees FY17 revs of $80-84 mln vs. $81.58 mln Capital IQ Consensus Estimate. Revenues for the second half of 2017 are expected to exist better than for the first half and the bespeak to bill ratio for the year is expected to exist above 1.
  • 4:34 am Mazor Robotics beats by $0.08, reports revs in-line (Pre-announced Q2 revs) (MZOR) :

  • Reports Q2 (Jun) loss of $0.05 per share, excluding non-recurring items, $0.08 better than the solitary analyst assess of ($0.13); revenues rose 86.7% year/year to $15.46 mln vs the $15.38 mln Capital IQ Consensus. The company pre-announced Q2 sales/orders in early July
  • The Company's indecorous margin for the three months ended June 30, 2017 was 69.4% compared to 76.9% in the year-ago second quarter. This expected diminish is attributed mainly to the higher manufacturing costs of the Mazor X compared to the Renaissance system and the inclusion of four Renaissance trade-ins to Mazor X
  • As previously announced, the Company received purchase orders for 19 systems in the 2017 second quarter and ended the quarter with a backlog of 14 systems.
  • 4:20 am On The Wires (:WIRES) :

  • Showa Denko (SHWDY) has decided to extend prices of its high-purity fluorine-based gases for electronics. Specifically, SDK will extend prices of high-purity FC-116 and FC-14 gases by about 500 yen (US$4.5) per kilogram each as from shipments on September 1, 2017. SDK will start contacting its customers concerning this charge increase. The company furthermore announced that it started to supply "low-carbon" hydrogen gas made from used plastics (low-carbon hydrogen) at its Kawasaki Plant to TOMOE SHOKAI Co., Ltd.'s Shinsuna Hydrogen Station located in Koto-ku, Tokyo terminal month.
  • Wirecard (WRCDF) and mobilcom-debitel announced a 'ground-breaking collaboration'. From today onwards, sum novel Android smartphones sold by mobilcom-debitel will arrive with the preinstalled mobile payment app boon.
  • Isogenica Ltd, a leader in the design and construction of innovative and highly diverse synthetic antibody libraries, announced a novel licensing deal with Takeda Pharmaceutical Company Limited (TKPYY). Under the terms of the agreement, Isogenica has granted Takeda licences to its family of llamdA VHH single-domain antibody libraries for the discovery, evolution and commercialisation of therapeutic products derived from these libraries. Isogenica is entitled to an upfront and annual licence payments. If antibodies are advanced into development, Isogenica is entitled to further licence fees, milestones and royalties.
  • Morrisons (MRWSY) is pleased to publish a major new, long-term wholesale supply initiative with McColl's, which will engage wholesale supply sales to more than 1bn in due course. Morrisons is to start supplying both Safeway products and national brands to 1,300 McColl's convenience shops and 350 newsagents across the UK1. The novel partnership will replace sum McColl's existing supply arrangements in time. Morrisons will supply McColl's shops, with a phased programme starting in January 2018. By the discontinue of 2018, the co expects total annualised wholesale sales to sum its partners to exist in excess of 700m (inc. tobacco). The co expects this novel initiative to compose an initial profit contribution in 2018/19, and extend thereafter.
  • Anglo American plc (NGLOY) announces the value of rough diamond sales (Global Sightholder Sales and Auction Sales) for De Beers' sixth sales cycle of 2017, amounting to $572 million.
  • 4:19 am AstraZeneca granted Breakthrough Therapy Designation by the FDA for acalabrutinib for the treatment of patients with mantle cell lymphoma who maintain received at least one prior therapy (AZN) : The Breakthrough Therapy Designation is designed to expedite the evolution and regulatory review of novel medicines that are intended to treat a sober condition and that maintain shown encouraging early clinical results, which demonstrate substantial improvement on a clinically-significant endpoint over available medicines and when there is significant unmet medical need.

    4:08 am British American Tobacco says the sober Fraud Office has opened a formal investigation into allegations of misconduct (BTI) : "As previously announced, they are investigating, through external legal advisers, allegations of misconduct. They maintain been co-operating with the sober Fraud Office ("SFO") and British American Tobacco ("BAT") has been informed that the SFO has now opened a formal investigation. BAT intends to co-operate with that investigation."

    3:58 am Worldpay & Vantiv (VNTV) granted extension by Panel on Takeovers and Mergers to finalize terms of their potential merger (WDDYF) :

    For reference, on 5 July 2017, Worldpay and Vantiv (VNTV) announced that they had reached agreement in principle on the key terms of a potential merger of Worldpay and Vantiv. The announcement stated that in accordance with Rule 2.6(a) of the UK Takeover Code, Vantiv is required to clarify its intentions by no later than 5.00pm on 1 August 2017 (the "PUSU Deadline"), by either announcing a solid objective to compose an tender or that it does not intend to compose an offer.

  • Positive discussions are continuing between Worldpay and Vantiv, but there can exist no certitude that a solid tender will exist forthcoming.
  • Therefore, the Board of Worldpay has requested that the Panel on Takeovers and Mergers (the "Panel") extend the PUSU Deadline. In the light of this request, an extension has been granted by the Panel and, in accordance with Rule 2.6(a) of the Code, Vantiv is required, by not later than 5.00pm on 8 August 2017, either to publish a solid objective to compose an tender in accordance with Rule 2.7 of the Code or to publish that it does not intend to compose an offer, in which case the announcement will exist treated as a statement to which Rule 2.8 of the Code applies.
  • 3:17 am On The Wires (:WIRES) :

  • Graa y Montero S.A.A. (GRAM) announced it signed an agreement with five banks to provide a $162.1 million credit line to GyM, the construction company of the Group, and an additional line of $100 million in order to develop future projects of the company.
  • R1 RCM Inc. (RCM) announced that Central Maine Healthcare, an integrated healthcare delivery system serving 400,000 people living in central, western, and mid-coast Maine, selected R1 for its Revenue Capture Solutions module.
  • CTI BioPharma Corp. (CTIC) announced that the first patient has been enrolled in PAC203, a side 2 clinical affliction of pacritinib in patients with primary myelofibrosis who maintain failed prior ruxolitinib therapy. PAC203 is designed to evaluate the dose response relationship for safety and efficacy (spleen volume reduction at 12 and 24 weeks) of three dose regimens: 100 mg once-daily, 100 mg twice-daily (BID) and 200 mg BID. The 200 mg BID dose regimen was used in the side 3 PERSIST-2 affliction of pacritinib in patients with myelofibrosis. The affliction is expected to enroll up to approximately 105 patients.
  • Hiab, Part of Cargotec (CYJBF), has entered into an agreement to acquire the loader crane business of one of Brazil's leading loader crane manufacturers Argos Guindastes Indstria e Comrcio Ltda. The acquisition is expected to engage dwelling during the third quarter 2017. The parties maintain agreed not to disclose the transaction value.
  • LivaNova PLC (LIVN) announced its latest VNS Therapy Systems received CE designate for expanded MRI labeling. VNS Therapy is now the only implantable device indicated for epilepsy therapy that allows patients to maintain high-quality 1.5T and 3T MRI scans without the exigency for special equipment.
  • 3:15 am generic Motors closes sale of Opel/Vauxhall business to the Groupe PSA (PEUGF) (GM) : The sale of GM Financial's European operations to Groupe PSA and BNP Paribas (BNPQY) is expected to close later this year, theme to various regulatory approvals.

    3:05 am Bank of Marin to acquire Bank of Napa (OTC: BNNP) for $51 mln in stock (BMRC) :

    Bank of Napa has two fork offices serving Napa County, and had assets of $246.1 million, total deposits of $217.7 million, and total loans of $139.3 million as of June 30, 2017.

  • The transaction will exist immediately accretive to BMRC's earnings, adding to shareholder value. BNNP shareholders will receive a fixed exchange ratio of 0.3070 shares of BMRC common stock for each share of BNNP common stock outstanding. Based on BMRC's closing stock charge of $65.95 on July 28, 2017, the transaction is valued at $51.0 million, or $20.25 per share of BNNP common stock. Such value will fluctuate with changes in the stock charge of BMRC. The total transaction value includes the value of BNNP options assumed by BMRC.
  • The transaction is expected to close in the fourth quarter of 2017, and upon closing the Bank will maintain approximately $2.4 billion in assets and operate twenty-two branches in five counties, including San Francisco, Marin, Sonoma, Napa and Alameda.


  • Direct Download of over 5500 Certification Exams

    3COM [8 Certification Exam(s) ]
    AccessData [1 Certification Exam(s) ]
    ACFE [1 Certification Exam(s) ]
    ACI [3 Certification Exam(s) ]
    Acme-Packet [1 Certification Exam(s) ]
    ACSM [4 Certification Exam(s) ]
    ACT [1 Certification Exam(s) ]
    Admission-Tests [13 Certification Exam(s) ]
    ADOBE [93 Certification Exam(s) ]
    AFP [1 Certification Exam(s) ]
    AICPA [2 Certification Exam(s) ]
    AIIM [1 Certification Exam(s) ]
    Alcatel-Lucent [13 Certification Exam(s) ]
    Alfresco [1 Certification Exam(s) ]
    Altiris [3 Certification Exam(s) ]
    Amazon [2 Certification Exam(s) ]
    American-College [2 Certification Exam(s) ]
    Android [4 Certification Exam(s) ]
    APA [1 Certification Exam(s) ]
    APC [2 Certification Exam(s) ]
    APICS [2 Certification Exam(s) ]
    Apple [69 Certification Exam(s) ]
    AppSense [1 Certification Exam(s) ]
    APTUSC [1 Certification Exam(s) ]
    Arizona-Education [1 Certification Exam(s) ]
    ARM [1 Certification Exam(s) ]
    Aruba [6 Certification Exam(s) ]
    ASIS [2 Certification Exam(s) ]
    ASQ [3 Certification Exam(s) ]
    ASTQB [8 Certification Exam(s) ]
    Autodesk [2 Certification Exam(s) ]
    Avaya [96 Certification Exam(s) ]
    AXELOS [1 Certification Exam(s) ]
    Axis [1 Certification Exam(s) ]
    Banking [1 Certification Exam(s) ]
    BEA [5 Certification Exam(s) ]
    BICSI [2 Certification Exam(s) ]
    BlackBerry [17 Certification Exam(s) ]
    BlueCoat [2 Certification Exam(s) ]
    Brocade [4 Certification Exam(s) ]
    Business-Objects [11 Certification Exam(s) ]
    Business-Tests [4 Certification Exam(s) ]
    CA-Technologies [21 Certification Exam(s) ]
    Certification-Board [10 Certification Exam(s) ]
    Certiport [3 Certification Exam(s) ]
    CheckPoint [41 Certification Exam(s) ]
    CIDQ [1 Certification Exam(s) ]
    CIPS [4 Certification Exam(s) ]
    Cisco [318 Certification Exam(s) ]
    Citrix [48 Certification Exam(s) ]
    CIW [18 Certification Exam(s) ]
    Cloudera [10 Certification Exam(s) ]
    Cognos [19 Certification Exam(s) ]
    College-Board [2 Certification Exam(s) ]
    CompTIA [76 Certification Exam(s) ]
    ComputerAssociates [6 Certification Exam(s) ]
    Consultant [2 Certification Exam(s) ]
    Counselor [4 Certification Exam(s) ]
    CPP-Institue [2 Certification Exam(s) ]
    CPP-Institute [1 Certification Exam(s) ]
    CSP [1 Certification Exam(s) ]
    CWNA [1 Certification Exam(s) ]
    CWNP [13 Certification Exam(s) ]
    Dassault [2 Certification Exam(s) ]
    DELL [9 Certification Exam(s) ]
    DMI [1 Certification Exam(s) ]
    DRI [1 Certification Exam(s) ]
    ECCouncil [21 Certification Exam(s) ]
    ECDL [1 Certification Exam(s) ]
    EMC [129 Certification Exam(s) ]
    Enterasys [13 Certification Exam(s) ]
    Ericsson [5 Certification Exam(s) ]
    ESPA [1 Certification Exam(s) ]
    Esri [2 Certification Exam(s) ]
    ExamExpress [15 Certification Exam(s) ]
    Exin [40 Certification Exam(s) ]
    ExtremeNetworks [3 Certification Exam(s) ]
    F5-Networks [20 Certification Exam(s) ]
    FCTC [2 Certification Exam(s) ]
    Filemaker [9 Certification Exam(s) ]
    Financial [36 Certification Exam(s) ]
    Food [4 Certification Exam(s) ]
    Fortinet [13 Certification Exam(s) ]
    Foundry [6 Certification Exam(s) ]
    FSMTB [1 Certification Exam(s) ]
    Fujitsu [2 Certification Exam(s) ]
    GAQM [9 Certification Exam(s) ]
    Genesys [4 Certification Exam(s) ]
    GIAC [15 Certification Exam(s) ]
    Google [4 Certification Exam(s) ]
    GuidanceSoftware [2 Certification Exam(s) ]
    H3C [1 Certification Exam(s) ]
    HDI [9 Certification Exam(s) ]
    Healthcare [3 Certification Exam(s) ]
    HIPAA [2 Certification Exam(s) ]
    Hitachi [30 Certification Exam(s) ]
    Hortonworks [4 Certification Exam(s) ]
    Hospitality [2 Certification Exam(s) ]
    HP [750 Certification Exam(s) ]
    HR [4 Certification Exam(s) ]
    HRCI [1 Certification Exam(s) ]
    Huawei [21 Certification Exam(s) ]
    Hyperion [10 Certification Exam(s) ]
    IAAP [1 Certification Exam(s) ]
    IAHCSMM [1 Certification Exam(s) ]
    IBM [1532 Certification Exam(s) ]
    IBQH [1 Certification Exam(s) ]
    ICAI [1 Certification Exam(s) ]
    ICDL [6 Certification Exam(s) ]
    IEEE [1 Certification Exam(s) ]
    IELTS [1 Certification Exam(s) ]
    IFPUG [1 Certification Exam(s) ]
    IIA [3 Certification Exam(s) ]
    IIBA [2 Certification Exam(s) ]
    IISFA [1 Certification Exam(s) ]
    Intel [2 Certification Exam(s) ]
    IQN [1 Certification Exam(s) ]
    IRS [1 Certification Exam(s) ]
    ISA [1 Certification Exam(s) ]
    ISACA [4 Certification Exam(s) ]
    ISC2 [6 Certification Exam(s) ]
    ISEB [24 Certification Exam(s) ]
    Isilon [4 Certification Exam(s) ]
    ISM [6 Certification Exam(s) ]
    iSQI [7 Certification Exam(s) ]
    ITEC [1 Certification Exam(s) ]
    Juniper [64 Certification Exam(s) ]
    LEED [1 Certification Exam(s) ]
    Legato [5 Certification Exam(s) ]
    Liferay [1 Certification Exam(s) ]
    Logical-Operations [1 Certification Exam(s) ]
    Lotus [66 Certification Exam(s) ]
    LPI [24 Certification Exam(s) ]
    LSI [3 Certification Exam(s) ]
    Magento [3 Certification Exam(s) ]
    Maintenance [2 Certification Exam(s) ]
    McAfee [8 Certification Exam(s) ]
    McData [3 Certification Exam(s) ]
    Medical [69 Certification Exam(s) ]
    Microsoft [374 Certification Exam(s) ]
    Mile2 [3 Certification Exam(s) ]
    Military [1 Certification Exam(s) ]
    Misc [1 Certification Exam(s) ]
    Motorola [7 Certification Exam(s) ]
    mySQL [4 Certification Exam(s) ]
    NBSTSA [1 Certification Exam(s) ]
    NCEES [2 Certification Exam(s) ]
    NCIDQ [1 Certification Exam(s) ]
    NCLEX [2 Certification Exam(s) ]
    Network-General [12 Certification Exam(s) ]
    NetworkAppliance [39 Certification Exam(s) ]
    NI [1 Certification Exam(s) ]
    NIELIT [1 Certification Exam(s) ]
    Nokia [6 Certification Exam(s) ]
    Nortel [130 Certification Exam(s) ]
    Novell [37 Certification Exam(s) ]
    OMG [10 Certification Exam(s) ]
    Oracle [279 Certification Exam(s) ]
    P&C [2 Certification Exam(s) ]
    Palo-Alto [4 Certification Exam(s) ]
    PARCC [1 Certification Exam(s) ]
    PayPal [1 Certification Exam(s) ]
    Pegasystems [12 Certification Exam(s) ]
    PEOPLECERT [4 Certification Exam(s) ]
    PMI [15 Certification Exam(s) ]
    Polycom [2 Certification Exam(s) ]
    PostgreSQL-CE [1 Certification Exam(s) ]
    Prince2 [6 Certification Exam(s) ]
    PRMIA [1 Certification Exam(s) ]
    PsychCorp [1 Certification Exam(s) ]
    PTCB [2 Certification Exam(s) ]
    QAI [1 Certification Exam(s) ]
    QlikView [1 Certification Exam(s) ]
    Quality-Assurance [7 Certification Exam(s) ]
    RACC [1 Certification Exam(s) ]
    Real-Estate [1 Certification Exam(s) ]
    RedHat [8 Certification Exam(s) ]
    RES [5 Certification Exam(s) ]
    Riverbed [8 Certification Exam(s) ]
    RSA [15 Certification Exam(s) ]
    Sair [8 Certification Exam(s) ]
    Salesforce [5 Certification Exam(s) ]
    SANS [1 Certification Exam(s) ]
    SAP [98 Certification Exam(s) ]
    SASInstitute [15 Certification Exam(s) ]
    SAT [1 Certification Exam(s) ]
    SCO [10 Certification Exam(s) ]
    SCP [6 Certification Exam(s) ]
    SDI [3 Certification Exam(s) ]
    See-Beyond [1 Certification Exam(s) ]
    Siemens [1 Certification Exam(s) ]
    Snia [7 Certification Exam(s) ]
    SOA [15 Certification Exam(s) ]
    Social-Work-Board [4 Certification Exam(s) ]
    SpringSource [1 Certification Exam(s) ]
    SUN [63 Certification Exam(s) ]
    SUSE [1 Certification Exam(s) ]
    Sybase [17 Certification Exam(s) ]
    Symantec [134 Certification Exam(s) ]
    Teacher-Certification [4 Certification Exam(s) ]
    The-Open-Group [8 Certification Exam(s) ]
    TIA [3 Certification Exam(s) ]
    Tibco [18 Certification Exam(s) ]
    Trainers [3 Certification Exam(s) ]
    Trend [1 Certification Exam(s) ]
    TruSecure [1 Certification Exam(s) ]
    USMLE [1 Certification Exam(s) ]
    VCE [6 Certification Exam(s) ]
    Veeam [2 Certification Exam(s) ]
    Veritas [33 Certification Exam(s) ]
    Vmware [58 Certification Exam(s) ]
    Wonderlic [2 Certification Exam(s) ]
    Worldatwork [2 Certification Exam(s) ]
    XML-Master [3 Certification Exam(s) ]
    Zend [6 Certification Exam(s) ]





    References :


    Dropmark : http://killexams.dropmark.com/367904/11888369
    Wordpress : http://wp.me/p7SJ6L-1Za
    Dropmark-Text : http://killexams.dropmark.com/367904/12857637
    Blogspot : http://killexamsbraindump.blogspot.com/2017/12/just-memorize-these-9a0-327-questions.html
    RSS Feed : http://feeds.feedburner.com/Pass4sure9a0-327AdobeCq55ComponentDeveloperAceExamBraindumpsWithRealQuestionsAndPracticeSoftware
    Box.net : https://app.box.com/s/qi4b1poqkhw89jqudxzjgai0o1106s0h






    Back to Main Page





    Killexams 9A0-327 exams | Killexams 9A0-327 cert | Pass4Sure 9A0-327 questions | Pass4sure 9A0-327 | pass-guaratee 9A0-327 | best 9A0-327 test preparation | best 9A0-327 training guides | 9A0-327 examcollection | killexams | killexams 9A0-327 review | killexams 9A0-327 legit | kill 9A0-327 example | kill 9A0-327 example journalism | kill exams 9A0-327 reviews | kill exam ripoff report | review 9A0-327 | review 9A0-327 quizlet | review 9A0-327 login | review 9A0-327 archives | review 9A0-327 sheet | legitimate 9A0-327 | legit 9A0-327 | legitimacy 9A0-327 | legitimation 9A0-327 | legit 9A0-327 check | legitimate 9A0-327 program | legitimize 9A0-327 | legitimate 9A0-327 business | legitimate 9A0-327 definition | legit 9A0-327 site | legit online banking | legit 9A0-327 website | legitimacy 9A0-327 definition | >pass 4 sure | pass for sure | p4s | pass4sure certification | pass4sure exam | IT certification | IT Exam | 9A0-327 material provider | pass4sure login | pass4sure 9A0-327 exams | pass4sure 9A0-327 reviews | pass4sure aws | pass4sure 9A0-327 security | pass4sure coupon | pass4sure 9A0-327 dumps | pass4sure cissp | pass4sure 9A0-327 braindumps | pass4sure 9A0-327 test | pass4sure 9A0-327 torrent | pass4sure 9A0-327 download | pass4surekey | pass4sure cap | pass4sure free | examsoft | examsoft login | exams | exams free | examsolutions | exams4pilots | examsoft download | exams questions | examslocal | exams practice |

    www.pass4surez.com | www.killcerts.com | www.search4exams.com | http://tractaricurteadearges.ro/